Evolocumab Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Evolocumab comprises 297 peer-reviewed publications across 15 journals, 41 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Hypercholesterolemia, Atherosclerosis, Acute Coronary Syndrome, and Dyslipidemias. Most recent publication: Proprotein convertase subtilisin/kexin type 9-CC-motif chemokine ligand 2 interactions link lipoprotein(a) composition to intermediate monocyte inflammation in coronary artery disease., Atheroscler Plus, 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.
    Zhou M, Wang H, Zeng X, et al. · Lancet · 2019
    PubMed: PMID 31248666 · NCT05976893 · Atherosclerosis
  2. Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries.
    Zeng H, Chen W, Zheng R, et al. · Lancet Glob Health · 2018
    PubMed: PMID 29653628 · NCT05976893 · Atherosclerosis
  3. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
    Schwartz GG, Steg PG, Szarek M, et al. · N Engl J Med · 2018
    PubMed: PMID 30403574 · NCT05976893 · Atherosclerosis
  4. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.
    Sabatine MS, Giugliano RP, Wiviott SD, et al. · N Engl J Med · 2015
    PubMed: PMID 25773607 · NCT05976893 · Atherosclerosis
  5. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
    Sabatine MS, Giugliano RP, Keech AC, et al. · N Engl J Med · 2017
    PubMed: PMID 28304224 · NCT03287609 (EVOPACS) · Acute Coronary Syndrome
  6. Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies for Acute Coronary Syndrome: A Narrative Review.
    Navarese EP, Kolodziejczak M, Kereiakes DJ, et al. · Ann Intern Med · 2017
    PubMed: PMID 26999484 · NCT03287609 (EVOPACS) · Acute Coronary Syndrome
  7. PCSK9 inhibition with orally administered NNC0385-0434 in hypercholesterolaemia: a randomised, double-blind, placebo-controlled and active-controlled phase 2 trial.
    Koren MJ, Descamps O, Hata Y, et al. · Lancet Diabetes Endocrinol · 2024
    PubMed: PMID 38310920 · NCT04992065 · Atherosclerosis
  8. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
    Cannon CP, Blazing MA, Giugliano RP, et al. · N Engl J Med · 2015
    PubMed: PMID 26039521 · NCT05976893 · Atherosclerosis

Primary-outcome results across pivotal trials

Per-arm reported values from Phase 2/3 and Phase 3 trials with results posted to ClinicalTrials.gov.

TrialIndicationPrimary endpointArmValue
NCT01516879
DESCARTES
HypercholesterolemiaPercent Change From Baseline in LDL-C at Week 52
Baseline and Week 52
Evolocumab-50.14 percent change (±1.24 Standard Error)
Placebo6.83 percent change (±1.75 Standard Error)
NCT01588496
TESLA
HypercholesterolemiaPart A: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12
Baseline and Week 12
Part A: Evolocumab-16.5 percent change (±6.7 Standard Error)
NCT01588496
TESLA
HypercholesterolemiaPart B: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12
Baseline and Week 12
Part B: Evolocumab-23.05 percent change (±3.78 Standard Error)
Part B: Placebo7.88 percent change (±5.26 Standard Error)
NCT01624142
TAUSSIG
HypercholesterolemiaNumber of Participants With Adverse Events
From first dose of study drug in Study 20110271 up to 30 days after the last dose or until the end of study date, whichever was earlier; median duration of treatment was 48.7 months.
HoFH94 Participants
HoFH76 Participants
HoFH38 Participants
HoFH6 Participants
HoFH2 Participants
HoFH29 Participants
HoFH3 Participants
HoFH4 Participants
Severe FH57 Participants
Severe FH5 Participants
Severe FH174 Participants
Severe FH143 Participants
Severe FH68 Participants
Severe FH14 Participants
Severe FH8 Participants
Severe FH18 Participants
NCT01763827
MENDEL-2
HypercholesterolemiaPercent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12
Baseline and Weeks 10 and 12
Evolocumab Q2W-56.93 percent change (±1.07 Standard Error)
Evolocumab QM-58.81 percent change (±1.00 Standard Error)
Ezetimibe (Q2W)-17.52 percent change (±1.46 Standard Error)
Ezetimibe (QM)-19.12 percent change (±1.39 Standard Error)
Placebo Q2W-0.43 percent change (±1.45 Standard Error)
Placebo QM-1.41 percent change (±1.37 Standard Error)
NCT01763827
MENDEL-2
HypercholesterolemiaPercent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12
Baseline and Week 12
Evolocumab Q2W-57.04 percent change (±1.23 Standard Error)
Evolocumab QM-56.12 percent change (±1.12 Standard Error)
Ezetimibe (Q2W)-17.75 percent change (±1.67 Standard Error)
Ezetimibe (QM)-18.57 percent change (±1.56 Standard Error)
Placebo Q2W0.10 percent change (±1.67 Standard Error)
Placebo QM-1.34 percent change (±1.54 Standard Error)
NCT01763866
LAPLACE-2
HypercholesterolemiaPercent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12
Baseline and Weeks 10 and 12
A10 EvoMab Q2W-61.41 percent change (±1.61 Standard Error)
A10 EvoMab QM-62.47 percent change (±1.83 Standard Error)
A10 EZE (Q2W)-23.88 percent change (±2.34 Standard Error)
A10 EZE (QM)-18.98 percent change (±2.57 Standard Error)
A10 PBO Q2W8.54 percent change (±2.24 Standard Error)
A10 PBO QM0.35 percent change (±2.60 Standard Error)
A80 EvoMab Q2W-61.80 percent change (±2.77 Standard Error)
A80 EvoMab QM-65.05 percent change (±2.42 Standard Error)
A80 EZE (Q2W)-16.85 percent change (±3.88 Standard Error)
A80 EZE (QM)-21.25 percent change (±3.42 Standard Error)
A80 PBO Q2W13.12 percent change (±3.99 Standard Error)
A80 PBO QM9.76 percent change (±3.39 Standard Error)
R40 EvoMab Q2W-59.08 percent change (±2.23 Standard Error)
R40 EvoMab QM-62.94 percent change (±2.44 Standard Error)
R40 PBO Q2W6.57 percent change (±3.11 Standard Error)
R40 PBO QM-0.02 percent change (±3.51 Standard Error)
R5 EvoMab Q2W-59.33 percent change (±1.74 Standard Error)
R5 EvoMab QM-63.79 percent change (±1.76 Standard Error)
R5 PBO Q2W7.55 percent change (±2.39 Standard Error)
R5 PBO QM2.79 percent change (±2.50 Standard Error)
S40 EvoMab Q2W-66.17 percent change (±2.93 Standard Error)
S40 EvoMab QM-62.45 percent change (±3.85 Standard Error)
S40 PBO Q2W3.26 percent change (±3.40 Standard Error)
S40 PBO QM6.00 percent change (±4.80 Standard Error)
NCT01763866
LAPLACE-2
HypercholesterolemiaPercent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12
Baseline and Week 12
A10 EvoMab Q2W-61.56 percent change (±1.81 Standard Error)
A10 EvoMab QM-58.19 percent change (±1.99 Standard Error)
A10 EZE (Q2W)-21.96 percent change (±2.63 Standard Error)
A10 EZE (QM)-17.08 percent change (±2.78 Standard Error)
A10 PBO Q2W9.86 percent change (±2.53 Standard Error)
A10 PBO QM0.97 percent change (±2.82 Standard Error)
A80 EvoMab Q2W-61.80 percent change (±3.04 Standard Error)
A80 EvoMab QM-58.68 percent change (±2.74 Standard Error)
A80 EZE (Q2W)-14.60 percent change (±4.29 Standard Error)
A80 EZE (QM)-19.80 percent change (±3.85 Standard Error)
A80 PBO Q2W14.49 percent change (±4.42 Standard Error)
A80 PBO QM11.83 percent change (±3.85 Standard Error)
R40 EvoMab Q2W-58.89 percent change (±2.58 Standard Error)
R40 EvoMab QM-52.40 percent change (±2.98 Standard Error)
R40 PBO Q2W9.42 percent change (±3.60 Standard Error)
R40 PBO QM2.59 percent change (±4.30 Standard Error)
R5 EvoMab Q2W-60.09 percent change (±1.94 Standard Error)
R5 EvoMab QM-59.40 percent change (±1.87 Standard Error)
R5 PBO Q2W8.12 percent change (±2.68 Standard Error)
R5 PBO QM5.10 percent change (±2.62 Standard Error)
S40 EvoMab Q2W-65.86 percent change (±3.05 Standard Error)
S40 EvoMab QM-57.02 percent change (±3.93 Standard Error)
S40 PBO Q2W4.70 percent change (±3.61 Standard Error)
S40 PBO QM3.40 percent change (±4.94 Standard Error)
NCT01763905
GAUSS-2
HypercholesterolemiaPercent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12
Baseline and Weeks 10 and 12
Evolocumab Q2W-56.11 percent change (±1.83 Standard Error)
Evolocumab QM-55.31 percent change (±1.53 Standard Error)
Ezetimibe (Q2W)-19.21 percent change (±2.40 Standard Error)
Ezetimibe (QM)-16.62 percent change (±2.03 Standard Error)
NCT01763905
GAUSS-2
HypercholesterolemiaPercent Change From Baseline in LDL-C at Week 12
Baseline and Week 12
Evolocumab Q2W-56.14 percent change (±1.91 Standard Error)
Evolocumab QM-52.60 percent change (±1.58 Standard Error)
Ezetimibe (Q2W)-18.08 percent change (±2.52 Standard Error)
Ezetimibe (QM)-15.05 percent change (±2.13 Standard Error)
NCT01763918
RUTHERFORD-2
HypercholesterolemiaPercent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12
Baseline and Weeks 10 and 12
Evolocumab Q2W-61.23 percent change (±1.71 Standard Error)
Evolocumab QM-63.25 percent change (±1.70 Standard Error)
Placebo Q2W-1.08 percent change (±2.41 Standard Error)
Placebo QM2.30 percent change (±2.41 Standard Error)
NCT01763918
RUTHERFORD-2
HypercholesterolemiaPercent Change From Baseline in LDL-C at Week 12
Baseline and Week 12
Evolocumab Q2W-61.25 percent change (±1.77 Standard Error)
Evolocumab QM-55.74 percent change (±2.25 Standard Error)
Placebo Q2W-2.02 percent change (±2.49 Standard Error)
Placebo QM5.53 percent change (±3.25 Standard Error)
NCT01764633
FOURIER
HypercholesterolemiaTime to Cardiovascular Death, Myocardial Infarction, Hospitalization for Unstable Angina, Stroke, or Coronary Revascularization
Events that occurred from randomization to the last confirmed survival status date; the median duration of follow-up was 26 months. KM estimates at 6, 12, 18, 24, 30 and 36 months are reported.
Evolocumab2.74 percentage of participants
Evolocumab10.91 percentage of participants
Evolocumab5.31 percentage of participants
Evolocumab9.13 percentage of participants
Evolocumab7.25 percentage of participants
Evolocumab12.57 percentage of participants
Placebo3.11 percentage of participants
Placebo6.01 percentage of participants
Placebo8.32 percentage of participants
Placebo10.66 percentage of participants
Placebo12.72 percentage of participants
Placebo14.64 percentage of participants
NCT01813422
GLAGOV
HypercholesterolemiaChange From Baseline in Percent Atheroma Volume at Week 78
Baseline and week 78
Evolocumab-0.955 percent atheroma volume (±0.190 Standard Error)
Placebo0.053 percent atheroma volume (±0.189 Standard Error)
NCT01849497HypercholesterolemiaPercentage of Participants With Full Administration of Evolocumab at Both Weeks 2 and 4
Week 2 and Week 4
Evolocumab AI/Pen89.2 percentage of participants
Evolocumab PFS96.0 percentage of participants
NCT01854918
OSLER-2
HypercholesterolemiaNumber of Participants With Adverse Events
48 weeks in the SOC-controlled period and up to 2 years in the All-IP period
Year 1: Evolocumab + Standard of Care57 Participants
Year 1: Evolocumab + Standard of Care225 Participants
Year 1: Evolocumab + Standard of Care17 Participants
Year 1: Evolocumab + Standard of Care5 Participants
Year 1: Evolocumab + Standard of Care1655 Participants
Year 1: Evolocumab + Standard of Care1070 Participants
Year 1: Evolocumab + Standard of Care55 Participants
Year 1: Evolocumab + Standard of Care195 Participants
Year 1: Standard of Care796 Participants
Year 1: Standard of Care519 Participants
Year 1: Standard of Care124 Participants
Year 1: Standard of Care7 Participants
Year 1: Standard of Care104 Participants
Year 1: Standard of Care0 Participants
Year 1: Standard of Care5 Participants
Year 1: Standard of Care0 Participants
Years 2-3: Evolocumab + SOC / Evolocumab + SOC45 Participants
Years 2-3: Evolocumab + SOC / Evolocumab + SOC1339 Participants
Years 2-3: Evolocumab + SOC / Evolocumab + SOC332 Participants
Years 2-3: Evolocumab + SOC / Evolocumab + SOC42 Participants
Years 2-3: Evolocumab + SOC / Evolocumab + SOC1789 Participants
Years 2-3: Evolocumab + SOC / Evolocumab + SOC379 Participants
Years 2-3: Evolocumab + SOC / Evolocumab + SOC16 Participants
Years 2-3: Evolocumab + SOC / Evolocumab + SOC35 Participants
Years 2-3: SOC / Evolocumab + SOC25 Participants
Years 2-3: SOC / Evolocumab + SOC11 Participants
Years 2-3: SOC / Evolocumab + SOC178 Participants
Years 2-3: SOC / Evolocumab + SOC3 Participants
Years 2-3: SOC / Evolocumab + SOC929 Participants
Years 2-3: SOC / Evolocumab + SOC700 Participants
Years 2-3: SOC / Evolocumab + SOC26 Participants
Years 2-3: SOC / Evolocumab + SOC214 Participants
NCT01879319HypercholesterolemiaPercentage of Participants With Full Administration of Evolocumab at Both Weeks 4 and 8
Weeks 4 and 8
Evolocumab AI/Pen91.5 Percentage of participants
Evolocumab AMD93.9 Percentage of participants
NCT01953328
AMG145
HypercholesterolemiaPercent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at the Mean of Weeks 10 and 12
Baseline and Weeks 10 and 12
A20 Evolocumab Q2W-74.82 percent change (±3.26 Standard Error)
A20 Evolocumab QM-76.93 percent change (±2.24 Standard Error)
A20 Placebo Q2W-0.42 percent change (±3.26 Standard Error)
A20 Placebo QM-2.67 percent change (±2.31 Standard Error)
A5 Evolocumab Q2W-73.70 percent change (±2.26 Standard Error)
A5 Evolocumab QM-69.98 percent change (±2.02 Standard Error)
A5 Placebo Q2W0.27 percent change (±2.21 Standard Error)
A5 Placebo QM3.91 percent change (±2.09 Standard Error)
NCT01953328
AMG145
HypercholesterolemiaPercent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12
Baseline and Week 12
A20 Evolocumab Q2W-74.46 percent change (±3.50 Standard Error)
A20 Evolocumab QM-70.36 percent change (±2.61 Standard Error)
A20 Placebo Q2W1.39 percent change (±3.51 Standard Error)
A20 Placebo QM-3.49 percent change (±2.67 Standard Error)
A5 Evolocumab Q2W-73.57 percent change (±2.48 Standard Error)
A5 Evolocumab QM-64.62 percent change (±2.12 Standard Error)
A5 Placebo Q2W1.28 percent change (±2.43 Standard Error)
A5 Placebo QM5.29 percent change (±2.19 Standard Error)
NCT01984424
GAUSS-3
HypercholesterolemiaPercent Change From Baseline in LDL-C at the Mean of Weeks 22 and 24
Baseline and weeks 22 and 24
Evolocumab-54.50 percent change (±1.39 Standard Error)
Ezetimibe-16.70 percent change (±1.91 Standard Error)
NCT01984424
GAUSS-3
HypercholesterolemiaPercent Change From Baseline in LDL-C at Week 24
Baseline and week 24
Evolocumab-52.76 percent change (±1.52 Standard Error)
Ezetimibe-16.69 percent change (±2.11 Standard Error)
NCT02189837
FLOREY
HypercholesterolemiaPercent Change From Baseline in Low-density Lipoprotein (LDL) Apolipoprotein B-100 Fractional Catabolic Rate (FCR)
Baseline (5 days prior to Day 1) and Day 50; plasma samples for fasting lipids were obtained at 0, 5, 10, 20, 30, 40, and 60 min, as well as at 1.5, 2, 2.5, 3, 4, 5, 6, 8, and 10 hours, and 2, 3, 4 and 5 days after D3-leucine administration.
Atorvastatin74.13 percent change (±24.84 Standard Error)
Evolocumab83.70 percent change (±26.06 Standard Error)
Evolocumab and Atorvastatin310.48 percent change (±26.68 Standard Error)
Placebo-5.07 percent change (±26.06 Standard Error)
NCT02207634
EBBINGHAUS
HypercholesterolemiaMean Change From Baseline in Spatial Working Memory Strategy Index of Executive Function (6-8 Boxes) Z Score
Assessments were conducted at Baseline and at weeks 24, 48, 96, 144 and end of study visit (median time on study was 19.4 months).
Evolocumab0.1134 Z score
Placebo0.1206 Z score
NCT02304484HypercholesterolemiaNumber of Participants With Adverse Events
From first dose of evolocumab up to 30 days after the last dose, or end of study, whichever was earlier, up to 108 weeks.
Evolocumab153 Participants
Evolocumab14 Participants
Evolocumab6 Participants
Evolocumab12 Participants
Evolocumab2 Participants
Evolocumab1 Participants
Evolocumab0 Participants
Evolocumab0 Participants
Evolocumab526 Participants
Evolocumab415 Participants
Evolocumab206 Participants
Evolocumab38 Participants
NCT02392559
HAUSER-RCT
HypercholesterolemiaPercent Change From Baseline to Week 24 in LDL-C
Baseline, Week 24
EvoMab 420 mg QM-44.53 percent change (±2.17 Standard Error)
Placebo-6.23 percent change (±3.08 Standard Error)
NCT02585895HypercholesterolemiaPercentage of Participants With Apheresis Avoidance at the End of Randomized Therapy
Week 5 and week 6
Apheresis10.0 percentage of participants
Evolocumab84.2 percentage of participants
NCT02624869
HAUSER-OLE
HypercholesterolemiaNumber of Participants With Treatment-emergent Adverse Events (TEAEs)
From first dose of evolocumab in this study up to and including 30 days after the last dose or up to the end of study date, whichever was earlier; up to 80 weeks.
HeFH (Evolocumab in Parent Study): Evolocumab 420 mg QM0 Participants
HeFH (Evolocumab in Parent Study): Evolocumab 420 mg QM0 Participants
HeFH (Evolocumab in Parent Study): Evolocumab 420 mg QM69 Participants
HeFH (Evolocumab in Parent Study): Evolocumab 420 mg QM56 Participants
HeFH (Evolocumab in Parent Study): Evolocumab 420 mg QM2 Participants
HeFH (Evolocumab in Parent Study): Evolocumab 420 mg QM1 Participants
HeFH (Evolocumab in Parent Study): Evolocumab 420 mg QM2 Participants
HeFH (Placebo in Parent Study): Evolocumab 420 mg QM36 Participants
HeFH (Placebo in Parent Study): Evolocumab 420 mg QM0 Participants
HeFH (Placebo in Parent Study): Evolocumab 420 mg QM0 Participants
HeFH (Placebo in Parent Study): Evolocumab 420 mg QM25 Participants
HeFH (Placebo in Parent Study): Evolocumab 420 mg QM2 Participants
HeFH (Placebo in Parent Study): Evolocumab 420 mg QM0 Participants
HeFH (Placebo in Parent Study): Evolocumab 420 mg QM4 Participants
HoFH: Evolocumab 420 mg QM2 Participants
HoFH: Evolocumab 420 mg QM7 Participants
HoFH: Evolocumab 420 mg QM5 Participants
HoFH: Evolocumab 420 mg QM2 Participants
HoFH: Evolocumab 420 mg QM0 Participants
HoFH: Evolocumab 420 mg QM0 Participants
HoFH: Evolocumab 420 mg QM0 Participants
NCT02634580
GAUSS-4
HypercholesterolemiaPercent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at the Mean of Weeks 10 and 12
Baseline and Weeks 10 and 12
Evolocumab-59.75 percent change (±2.30 Standard Error)
Ezetimibe-20.39 percent change (±3.19 Standard Error)
NCT02634580
GAUSS-4
HypercholesterolemiaPercent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12
Baseline and week 12
Evolocumab-59.27 percent change (±2.50 Standard Error)
Ezetimibe-19.13 percent change (±3.45 Standard Error)
NCT02662569
BERSON
HyperlipidemiasPercent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12
Baseline and weeks 10 and 12
Evolocumab Q2W-65.35 percent change (±3.09 Standard Error)
Evolocumab QM-69.05 percent change (±2.96 Standard Error)
Placebo Q2W4.94 percent change (±3.48 Standard Error)
Placebo QM0.99 percent change (±3.31 Standard Error)
NCT02662569
BERSON
HyperlipidemiasPercent Change From Baseline in LDL-C at Week 12
Baseline and week 12
Evolocumab Q2W-64.66 percent change (±3.20 Standard Error)
Evolocumab QM-62.30 percent change (±3.02 Standard Error)
Placebo Q2W7.10 percent change (±3.66 Standard Error)
Placebo QM2.63 percent change (±3.41 Standard Error)
NCT02729025
ANITSCHKOW
HyperlipidemiasPercent Change From Baseline in Maximum Target-to-background Ratio in the Most Diseased Segment of the Index Vessel at Week 16
Baseline and week 16
Evolocumab 420 mg QM-8.31 percent change (±1.67 Standard Error)
Placebo-5.31 percent change (±1.67 Standard Error)
NCT02739984
BANTING
HypercholesterolemiaPercent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12
Baseline and Weeks 10 and 12
Evolocumab-64.98 percent change (±1.31 Standard Error)
Placebo-0.84 percent change (±1.76 Standard Error)
NCT02739984
BANTING
HypercholesterolemiaPercent Change From Baseline in LDL-C at Week 12
Baseline and week 12
Evolocumab-54.28 percent change (±1.42 Standard Error)
Placebo-1.14 percent change (±1.92 Standard Error)
NCT02833844HyperlipidemiasPercent Change From Baseline in LDL-C at Week 24
Baseline, Week 24
Double-Blind Evolocumab-55.23 percent change (±1.52 Standard Error)
Double-Blind Placebo1.68 percent change (±2.03 Standard Error)
NCT02867813
FOURIER OLE
HypercholesterolemiaNumber of Participants Who Experienced an Adverse Event
Up to 5 years
Evolocumab Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent Study2084 Participants
Placebo Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent Study2144 Participants
NCT03080935DyslipidemiasNumber of Participants Who Experienced an Adverse Event
Up to 5 years
Evolocumab Once Every 2 Weeks (Q2W) or Once Every Month (QM) in Parent Study810 Participants
Placebo Once Every 2 Weeks (Q2W) or Once Every Month (QM) in Parent Study686 Participants
NCT03433755HypercholesterolemiaCo-Primary Endpoint: Percent Change From Baseline in LDL-C at Week 12
Baseline, Week 12
Evolocumab 140 mg Q2W-68.39 percent change (±3.55 Standard Error)
Evolocumab 420 mg QM-63.09 percent change (±3.42 Standard Error)
Placebo Q2W2.48 percent change (±4.18 Standard Error)
Placebo QM2.72 percent change (±4.25 Standard Error)
NCT03433755HypercholesterolemiaCo-Primary Endpoint: Percent Change From Baseline in LDL-C: Mean of Weeks 10 and 12
Baseline, Weeks 10 and 12
Evolocumab 140 mg Q2W-68.86 percent change (±3.27 Standard Error)
Evolocumab 420 mg QM-70.10 percent change (±3.21 Standard Error)
Placebo Q2W1.88 percent change (±3.72 Standard Error)
Placebo QM-0.36 percent change (±3.78 Standard Error)
NCT03570697Coronary Artery DiseaseAbsolute Change From Baseline in Minimum FCT
Baseline, week 50
Evolocumab42.7 µm (±5.1 Standard Error)
Placebo21.5 µm (±5.2 Standard Error)
NCT03689946HyperlipidemiasChange in Noncalcified Coronary Artery Plaque Volume (NCPV)
baseline (pre-treatment) and 18 months after of treatment
Evolocumab, F18-NaF PET, CCTA-45 mm^3 (±64 Standard Deviation)

Publications by year

1974–2026: 297 publications.

1974
1
1979
1
1986
1
1992
1
1994
1
1995
1
1996
1
1998
4
1999
1
2000
3
2001
4
2002
2
2003
4
2004
3
2005
2
2006
6
2007
2
2009
7
2010
4
2011
4
2012
10
2013
15
2014
18
2015
15
2016
7
2017
18
2018
14
2019
23
2020
29
2021
23
2022
22
2023
13
2024
16
2025
15
2026
6

Publications by indication

Hypercholesterolemia (128)

  • Efficacy and Safety of Very Low Achieved LDL Cholesterol in Patients With Previous Ischemic Stroke.
    Circulation · 2026 · PMID 41178569 · NCT01764633
  • Intensive Lowering of LDL Cholesterol Levels With Evolocumab in Autoimmune or Inflammatory Diseases: An Analysis of the FOURIER Trial.
    Circulation · 2025 · PMID 40255182 · NCT01764633
  • Quantification of LDL-Cholesterol Corrected for Molar Concentration of Lipoprotein(a).
    Cardiovasc Drugs Ther · 2024 · PMID 36435949 · NCT02739984
  • In-silico trial emulation to predict the cardiovascular protection of new lipid-lowering drugs: an illustration through the design of the SIRIUS programme.
    Eur J Prev Cardiol · 2024 · PMID 39101472 · NCT05974345
  • Evolocumab in paediatric heterozygous familial hypercholesterolaemia: cognitive function during 80 weeks of open-label extension treatment.
    Eur J Prev Cardiol · 2024 · PMID 37855448 · NCT02624869

Atherosclerosis (56)

  • Effect of evolocumab on saphenous vein graft patency after coronary artery bypass surgery (NEWTON-CABG CardioLink-5): an international, randomised, double-blind, placebo-controlled trial.
    Lancet · 2025 · PMID 40907505 · NCT03900026
  • Endothelial function in high-risk patients with ezetimibe therapy.
    J Clin Lipidol · 2025 · PMID 40813220 · NCT03626831
  • PCSK9 inhibition with orally administered NNC0385-0434 in hypercholesterolaemia: a randomised, double-blind, placebo-controlled and active-controlled phase 2 trial.
    Lancet Diabetes Endocrinol · 2024 · PMID 38310920 · NCT04992065
  • Past, Present, and Future of Radiation-Induced Cardiotoxicity: Refinements in Targeting, Surveillance, and Risk Stratification.
    JACC CardioOncol · 2024 · PMID 34604796 · NCT05976893
  • Inhibition of PCSK9 with evolocumab modulates lipoproteins and monocyte activation in high-risk ASCVD subjects.
    Atherosclerosis · 2024 · PMID 38583289 · NCT03829046

Acute Coronary Syndrome (25)

  • Effect of Early Initiation of Evolocumab on Lipid Profiles Changes in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
    Korean Circ J · 2026 · PMID 41560483 · NCT05661552
  • Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes - exploratory analysis of the EMSIACS trial.
    Sci Rep · 2025 · PMID 41309899 · NCT04100434
  • Lipoprotein(a) concentrations in acute myocardial infarction patients are not indicative of levels at six month follow-up.
    Eur Heart J Open · 2023 · PMID 37095769 · NCT04082442
  • The Trajectory of Lipoprotein(a) During the Peri- and Early Postinfarction Period and the Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition.
    Am J Cardiol · 2022 · PMID 35314069 · NCT04082442
  • Effects of Evolocumab Added to Moderate-Intensity Statin Therapy in Chinese Patients With Acute Coronary Syndrome: The EMSIACS Trial Study Protocol.
    Front Physiol · 2021 · PMID 34887772 · NCT04100434

Dyslipidemias (24)

  • Proprotein convertase subtilisin/kexin type 9-CC-motif chemokine ligand 2 interactions link lipoprotein(a) composition to intermediate monocyte inflammation in coronary artery disease.
    Atheroscler Plus · 2026 · PMID 42007426 · NCT04613167
  • Treatment with PCSK9 inhibitors influences microRNAs expression and changes of arterial wall properties: a randomized controlled trial.
    Eur J Med Res · 2025 · PMID 40001082 · NCT04613167
  • Effects of proprotein convertase subtilisin-kexin type 9 inhibitors on inflammatory and hemostatic parameters in post myocardial infarction patients.
    Eur J Pharmacol · 2024 · PMID 38070635 · NCT04613167
  • Rationale and design of the expanded combination of evolocumab plus empagliflozin in diabetes: EXCEED-BHS3 trial.
    Ther Adv Chronic Dis · 2024 · PMID 33062236 · NCT03932721
  • Long-Term Efficacy of Evolocumab in Patients With or Without Multivessel Coronary Disease.
    J Am Coll Cardiol · 2024 · PMID 38325990 · NCT03080935

Hyperlipidemias (12)

  • Effects of Evolocumab on Coronary Plaque Composition and Microcalcification Activity by Coronary PET and CT Angiography.
    JACC Cardiovasc Imaging · 2025 · PMID 40178463 · NCT03689946
  • Effects of evolocumab therapy and low LDL-C levels on vitamin E and steroid hormones in Chinese and global patients with type 2 diabetes.
    Endocrinol Diabetes Metab · 2024 · PMID 32318641 · NCT02662569
  • Long-term effects of evolocumab in participants with HIV and dyslipidemia: results from the open-label extension period.
    AIDS · 2022 · PMID 35025817 · NCT02833844
  • Metabolic effects of PCSK9 inhibition with Evolocumab in subjects with elevated Lp(a).
    Lipids Health Dis · 2021 · PMID 32393252 · NCT02729025
  • Potent lipoprotein(a) lowering following apolipoprotein(a) antisense treatment reduces the pro-inflammatory activation of circulating monocytes in patients with elevated lipoprotein(a).
    Eur Heart J · 2021 · PMID 32268367 · NCT02729025

Coronary Artery Disease (11)

  • Short-term lesion-level impact of extensive LDL-C reduction with statins and PCSK9 inhibitors: a pre-specified subgroup analysis of the randomized FITTER trial.
    Clin Res Cardiol · 2026 · PMID 41870626 · NCT04141579
  • Changes in non-culprit coronary lesions with PCSK9 inhibitors: the randomised, placebo-controlled FITTER trial.
    EuroIntervention · 2025 · PMID 40828313 · NCT04141579
  • Achieved levels of apolipoprotein B and plaque composition after acute coronary syndromes: Insights from HUYGENS.
    Atherosclerosis · 2025 · PMID 40020597 · NCT03570697
  • Impact of evolocumab on plaque phenotypic changes in patients with acute coronary syndrome and elevated lipoprotein(a) levels: a HUYGENS secondary analysis.
    Eur J Prev Cardiol · 2025 · PMID 40424182 · NCT03570697
  • Functional and morphological improvement of significant non-culprit coronary artery stenosis by LDL-C reduction with a PCSK9 antibody: Rationale and design of the randomized FITTER trial.
    Heliyon · 2024 · PMID 39430462 · NCT04141579

Publications by journal

Trial-results highlights

Clinical trials investigated the effects of Evolocumab on cholesterol levels. In the NCT01516879 (DESCARTES) study, participants treated with Evolocumab showed a -50.14 percent change from baseline in LDL-C at Week 52, compared to a 6.83 percent change in the placebo arm. The NCT01763827 (MENDEL-2) trial reported LDL-C percent change from baseline at the mean of Weeks 10 and 12, with Evolocumab Q2W showing a -56.93 percent change and Evolocumab QM showing a -58.81 percent change. In the same study, at Week 12, Evolocumab Q2W showed a -57.04 percent change and Evolocumab QM showed a -56.12 percent change. The NCT01763866 (LAPLACE-2) study also assessed LDL-C percent change from baseline at the mean of Weeks 10 and 12, with A10 EvoMab Q2W showing a -61.41 percent change and A10 EvoMab QM showing a -62.47 percent change. At Week 12 in LAPLACE-2, A10 EvoMab Q2W showed a -61.56 percent change and A10 EvoMab QM showed a -58.19 percent change.

Further studies also examined LDL-C changes. In the NCT01588496 (TESLA) trial, Part A reported a -16.5 percent change from baseline in LDL-C at Week 12 for the Evolocumab arm. In Part B of the TESLA trial, the Evolocumab arm showed a -23.05 percent change from baseline in LDL-C at Week 12, compared to a 7.88 percent change in the placebo arm.

Regarding adverse events, the NCT01624142 (TAUSSIG) study, which focused on participants with HoFH, reported the number of participants with adverse events. The reported counts for participants with adverse events in the HoFH group were: 94 participants, 76 participants, 38 participants, 6 participants, 2 participants, and 29 participants. The median duration of treatment in this study was 48.7 months.

All values are sourced from primary registry reporting; individual papers should be consulted for clinical decisions.

All Evolocumab publications (297)

2026 (6 papers)

  1. Proprotein convertase subtilisin/kexin type 9-CC-motif chemokine ligand 2 interactions link lipoprotein(a) composition to intermediate monocyte inflammation in coronary artery disease.
    Ugovšek S, Rehberger Likozar A, Levstek T, et al. · Atheroscler Plus · 2026 · Derived
    PubMed: PMID 42007426 · NCT04613167 (GEBI) · Dyslipidemias
  2. Effect of Early Initiation of Evolocumab on Lipid Profiles Changes in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
    Roh JW, Lee OH, Kim Y, et al. · Korean Circ J · 2026 · Derived
    PubMed: PMID 41560483 · NCT05661552 (C-STAR) · Acute Coronary Syndrome
  3. Efficacy and Safety of Very Low Achieved LDL Cholesterol in Patients With Previous Ischemic Stroke.
    Monguillon V, Kelly PJ, O'Donoghue ML, et al. · Circulation · 2026 · Derived
    PubMed: PMID 41178569 · NCT01764633 (FOURIER) · Hypercholesterolemia
  4. Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes: Results From the VESALIUS-CV Trial.
    Marston NA, Bohula EA, Bhatia AK, et al. · JAMA · 2026 · Derived
    PubMed: PMID 41903215 · NCT03872401 (VESALIUS-CV) · Coronary Disease
  5. Short-term lesion-level impact of extensive LDL-C reduction with statins and PCSK9 inhibitors: a pre-specified subgroup analysis of the randomized FITTER trial.
    Los J, Mensink FB, Reda Morsy MM, et al. · Clin Res Cardiol · 2026 · Derived
    PubMed: PMID 41870626 · NCT04141579 (FITTER) · Coronary Artery Disease
  6. Evolocumab in Patients without a Previous Myocardial Infarction or Stroke.
    Bohula EA, Marston NA, Bhatia AK, et al. · N Engl J Med · 2026 · Derived
    PubMed: PMID 41211925 · NCT03872401 (VESALIUS-CV) · Coronary Disease

2025 (15 papers)

  1. Intensive Lowering of LDL Cholesterol Levels With Evolocumab in Autoimmune or Inflammatory Diseases: An Analysis of the FOURIER Trial.
    Zimerman A, Kunzler ALF, Weber BN, et al. · Circulation · 2025 · Derived
    PubMed: PMID 40255182 · NCT01764633 (FOURIER) · Hypercholesterolemia
  2. Effect of evolocumab on saphenous vein graft patency after coronary artery bypass surgery (NEWTON-CABG CardioLink-5): an international, randomised, double-blind, placebo-controlled trial.
    Verma S, Leiter LA, Teoh H, et al. · Lancet · 2025 · Derived
    PubMed: PMID 40907505 · NCT03900026 (NEWTON-CABG) · Atherosclerosis
  3. Treatment with PCSK9 inhibitors influences microRNAs expression and changes of arterial wall properties: a randomized controlled trial.
    Rehberger Likozar A, Levstek T, Karun T, et al. · Eur J Med Res · 2025 · Derived
    PubMed: PMID 40001082 · NCT04613167 (GEBI) · Dyslipidemias
  4. Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial.
    Raal FJ, Mehta V, Kayikcioglu M, et al. · Lancet Diabetes Endocrinol · 2025 · Derived
    PubMed: PMID 39870096 · NCT04034485 · Homozygous Familial Hypercholesterolemia
  5. Evolocumab for early reduction of LDL-C levels in patients with acute ischemic stroke: a randomized controlled trial.
    Qiu X, Liang Y, Wei Y, et al. · Front Neurol · 2025 · Derived
    PubMed: PMID 39764289 · NCT05697185 (SEEIS) · Ischemic Stroke
  6. Changes in non-culprit coronary lesions with PCSK9 inhibitors: the randomised, placebo-controlled FITTER trial.
    Mensink FB, Los J, Reda Morsy MM, et al. · EuroIntervention · 2025 · Derived
    PubMed: PMID 40828313 · NCT04141579 (FITTER) · Coronary Artery Disease
  7. Impact of evolocumab on coronary physiology and microstructure in de-novo heart transplant recipients.
    Karim SR, Jensen NM, Holck EN, et al. · J Heart Lung Transplant · 2025 · Derived
    PubMed: PMID 40846112 · NCT03734211 (EVOLVD) · Vascular Diseases
  8. Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes - exploratory analysis of the EMSIACS trial.
    Jing A, Wang J, Zhang M, et al. · Sci Rep · 2025 · Derived
    PubMed: PMID 41309899 · NCT04100434 (EMSIACS) · Acute Coronary Syndrome
  9. Effects of Evolocumab on Coronary Plaque Composition and Microcalcification Activity by Coronary PET and CT Angiography.
    Han D, Tzolos E, Park R, et al. · JACC Cardiovasc Imaging · 2025 · Derived
    PubMed: PMID 40178463 · NCT03689946 · Hyperlipidemias
  10. Endothelial function in high-risk patients with ezetimibe therapy.
    Günes-Altan M, Bosch A, Striepe K, et al. · J Clin Lipidol · 2025 · Derived
    PubMed: PMID 40813220 · NCT03626831 (EVO) · Atherosclerosis
  11. Achieved levels of apolipoprotein B and plaque composition after acute coronary syndromes: Insights from HUYGENS.
    Fujino M, Di Giovanni G, Butters Bhsc J, et al. · Atherosclerosis · 2025 · Derived
    PubMed: PMID 40020597 · NCT03570697 · Coronary Artery Disease
  12. Impact of evolocumab on plaque phenotypic changes in patients with acute coronary syndrome and elevated lipoprotein(a) levels: a HUYGENS secondary analysis.
    Di Giovanni G, Fujino M, Kataoka Y, et al. · Eur J Prev Cardiol · 2025 · Derived
    PubMed: PMID 40424182 · NCT03570697 · Coronary Artery Disease
  13. Design of the "EAST" strategy in patients with symptomatic intracranial atherosclerotic stenosis.
    Dai J, Zhao H, Chen X, et al. · Front Neurol · 2025 · Derived
    PubMed: PMID 40417113 · NCT05741086 (EAST-ICAS) · Stroke
  14. Successful use of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Hypertriglyceridemia-induced Acute Pancreatitis: A Case Report.
    Qi R, Liu H, Li X, et al. · Curr Cardiol Rev · 2025 · Background
    PubMed: PMID 39773061 · NCT07388420
  15. Lipid-lowering effect of evolocumab in hypertriglyceridemia-induced acute pancreatitis.
    Chen H, Li X, Chen J, et al. · Eur J Pharmacol · 2025 · Background
    PubMed: PMID 40967356 · NCT07388420

2024 (16 papers)

  1. PCSK9 inhibition with orally administered NNC0385-0434 in hypercholesterolaemia: a randomised, double-blind, placebo-controlled and active-controlled phase 2 trial.
    Koren MJ, Descamps O, Hata Y, et al. · Lancet Diabetes Endocrinol · 2024 · Trial result
    PubMed: PMID 38310920 · NCT04992065 · Atherosclerosis
  2. Past, Present, and Future of Radiation-Induced Cardiotoxicity: Refinements in Targeting, Surveillance, and Risk Stratification.
    Bergom C, Bradley JA, Ng AK, et al. · JACC CardioOncol · 2024 · Trial result
    PubMed: PMID 34604796 · NCT05976893 · Atherosclerosis
  3. Inhibition of PCSK9 with evolocumab modulates lipoproteins and monocyte activation in high-risk ASCVD subjects.
    Rosenson RS, Tate A, Mar P, et al. · Atherosclerosis · 2024 · Derived
    PubMed: PMID 38583289 · NCT03829046 · Atherosclerosis
  4. Quantification of LDL-Cholesterol Corrected for Molar Concentration of Lipoprotein(a).
    Rosenson RS, López JAG, Monsalvo ML, et al. · Cardiovasc Drugs Ther · 2024 · Derived
    PubMed: PMID 36435949 · NCT02739984 (BANTING) · Hypercholesterolemia
  5. Effects of proprotein convertase subtilisin-kexin type 9 inhibitors on inflammatory and hemostatic parameters in post myocardial infarction patients.
    Rehberger Likozar A, Ugovšek S, Šebeštjen M, et al. · Eur J Pharmacol · 2024 · Derived
    PubMed: PMID 38070635 · NCT04613167 (GEBI) · Dyslipidemias
  6. Functional and morphological improvement of significant non-culprit coronary artery stenosis by LDL-C reduction with a PCSK9 antibody: Rationale and design of the randomized FITTER trial.
    Mensink FB, Los J, Oemrawsingh RM, et al. · Heliyon · 2024 · Derived
    PubMed: PMID 39430462 · NCT04141579 (FITTER) · Coronary Artery Disease
  7. Randomized Trial of Cholesterol Lowering With Evolocumab for Cardiac Allograft Vasculopathy in Heart Transplant Recipients.
    Broch K, Lemström KB, Gustafsson F, et al. · JACC Heart Fail · 2024 · Derived
    PubMed: PMID 38934968 · NCT03734211 (EVOLVD) · Vascular Diseases
  8. Rationale and design of the expanded combination of evolocumab plus empagliflozin in diabetes: EXCEED-BHS3 trial.
    Breder I, Cunha Breder J, Bonilha I, et al. · Ther Adv Chronic Dis · 2024 · Derived
    PubMed: PMID 33062236 · NCT03932721 (EXCEED-BHS3) · Dyslipidemias
  9. Effects of evolocumab therapy and low LDL-C levels on vitamin E and steroid hormones in Chinese and global patients with type 2 diabetes.
    Blom DJ, Chen J, Yuan Z, et al. · Endocrinol Diabetes Metab · 2024 · Derived
    PubMed: PMID 32318641 · NCT02662569 (BERSON) · Hyperlipidemias
  10. In-silico trial emulation to predict the cardiovascular protection of new lipid-lowering drugs: an illustration through the design of the SIRIUS programme.
    Angoulvant D, Granjeon-Noriot S, Amarenco P, et al. · Eur J Prev Cardiol · 2024 · Derived
    PubMed: PMID 39101472 · NCT05974345 (SIRIUS) · Hypercholesterolemia
  11. Evolocumab in paediatric heterozygous familial hypercholesterolaemia: cognitive function during 80 weeks of open-label extension treatment.
    Santos RD, Ruzza A, Wang B, et al. · Eur J Prev Cardiol · 2024 · Background
    PubMed: PMID 37855448 · NCT02624869 (HAUSER-OLE) · Hypercholesterolemia
  12. Evolocumab Treatment in Pediatric Patients With Homozygous Familial Hypercholesterolemia: Pooled Data From Three Open-Label Studies.
    Raal FJ, Hegele RA, Ruzza A, et al. · Arterioscler Thromb Vasc Biol · 2024 · Background
    PubMed: PMID 38545781 · NCT02624869 (HAUSER-OLE) · Hypercholesterolemia
  13. Long-Term Efficacy of Evolocumab in Patients With or Without Multivessel Coronary Disease.
    McClintick DJ, O'Donoghue ML, De Ferrari GM, et al. · J Am Coll Cardiol · 2024 · Background
    PubMed: PMID 38325990 · NCT03080935 · Dyslipidemias
  14. PCSK9 Inhibitors in Multi-Branch Lesions in Coronary Artery Disease with Substandard Lipid-Lowering Effects.
    Lu W, Wang L, Du C, et al. · Altern Ther Health Med · 2024 · Background
    PubMed: PMID 38064616 · NCT07388420
  15. A Comparison of Ezetimibe and Evolocumab for Atherogenic Lipid Reduction in Four Patient Populations: A Pooled Efficacy and Safety Analysis of Three Phase 3 Studies.
    Koren MJ, Jones PH, Robinson JG, et al. · Cardiol Ther · 2024 · Background
    PubMed: PMID 32564340 · NCT01763905 (GAUSS-2) · Hypercholesterolemia
  16. Rationale and design of the effect of evolocumab in patients at high cardiovascular risk without prior myocardial infarction or stroke (VESALIUS-CV) trial.
    Bohula EA, Marston NA, Ruzza A, et al. · Am Heart J · 2024 · Background
    PubMed: PMID 38160917 · NCT03872401 (VESALIUS-CV) · Coronary Disease

2023 (13 papers)

  1. Report on cardiovascular health and diseases in China 2021: an updated summary.
    In China TWCOTROCHAD, Hu SS · J Geriatr Cardiol · 2023 · Trial result
    PubMed: PMID 37416519 · NCT05976893 · Atherosclerosis
  2. Lipoprotein(a) concentrations in acute myocardial infarction patients are not indicative of levels at six month follow-up.
    Ziogos E, Vavuranakis MA, Harb T, et al. · Eur Heart J Open · 2023 · Derived
    PubMed: PMID 37095769 · NCT04082442 (EVACS II) · Acute Coronary Syndrome
  3. Contribution of intestinal triglyceride-rich lipoproteins to residual atherosclerotic cardiovascular disease risk in individuals with type 2 diabetes on statin therapy.
    Taskinen MR, Matikainen N, Björnson E, et al. · Diabetologia · 2023 · Derived
    PubMed: PMID 37775612 · NCT02948777 · Cardiovascular Diseases
  4. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial.
    Ray KK, Troquay RPT, Visseren FLJ, et al. · Lancet Diabetes Endocrinol · 2023 · Derived
    PubMed: PMID 36620965 · NCT03060577 (ORION-3) · Atherosclerosis
  5. PCSK9 Inhibition During the Inflammatory Stage of SARS-CoV-2 Infection.
    Navarese EP, Podhajski P, Gurbel PA, et al. · J Am Coll Cardiol · 2023 · Derived
    PubMed: PMID 36653090 · NCT04941105 (IMPACT-SIRIO 5) · COVID-19
  6. Predictors of functional and morphological arterial wall properties in coronary artery disease patients with increased lipoprotein (a) levels before and after treatment with proprotein convertase subtilisin-kexin type 9 inhibitors.
    Likozar AR, Šebeštjen M · Cardiovasc Ultrasound · 2023 · Derived
    PubMed: PMID 37580777 · NCT04613167 (GEBI) · Dyslipidemias
  7. Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE.
    Gaba P, O'Donoghue ML, Park JG, et al. · Circulation · 2023 · Derived
    PubMed: PMID 36779348 · NCT01764633 (FOURIER) · Hypercholesterolemia
  8. Impact of evolocumab on the pharmacodynamic profiles of clopidogrel in patients with atherosclerotic cardiovascular disease: a randomised, double-blind, placebo-controlled study.
    Franchi F, Ortega-Paz L, Rollini F, et al. · EuroIntervention · 2023 · Derived
    PubMed: PMID 36602868 · NCT03096288 · Atherosclerosis
  9. Restoring mortality data in the FOURIER cardiovascular outcomes trial of evolocumab in patients with cardiovascular disease: a reanalysis based on regulatory data.
    Erviti J, Wright J, Bassett K, et al. · BMJ Open · 2023 · Derived
    PubMed: PMID 36585131 · NCT01764633 (FOURIER) · Hypercholesterolemia
  10. Pharmacological interventions for asymptomatic carotid stenosis.
    Clezar CN, Flumignan CD, Cassola N, et al. · Cochrane Database Syst Rev · 2023 · Derived
    PubMed: PMID 37565307 · NCT04730973 (CARUSO) · Carotid Artery Diseases
  11. Efficacy and Safety of Evolocumab in Chinese Patients with Primary Hypercholesterolemia and Mixed Dyslipidemia: 12-Week Primary Results of the HUA TUO Randomized Clinical Trial.
    Tan H, Li W, Huang Z, et al. · Cardiol Ther · 2023 · Background
    PubMed: PMID 36802321 · NCT07388420
  12. SIRT3 mediates the effects of PCSK9 inhibitors on inflammation, autophagy, and oxidative stress in endothelial cells.
    D'Onofrio N, Prattichizzo F, Marfella R, et al. · Theranostics · 2023 · Background
    PubMed: PMID 36632236 · NCT06231459 (CytoEx-PCSK9) · Hyperlipoproteinemia Type II
  13. Assessment of Atherothrombotic Risk in Patients With Type 2 Diabetes Mellitus.
    Berg DD, Moura FA, Bellavia A, et al. · J Am Coll Cardiol · 2023 · Background
    PubMed: PMID 37344040 · NCT01764633 (FOURIER) · Hypercholesterolemia

2022 (22 papers)

  1. Cancer statistics in China and United States, 2022: profiles, trends, and determinants.
    Xia C, Dong X, Li H, et al. · Chin Med J (Engl) · 2022 · Trial result
    PubMed: PMID 35143424 · NCT05976893 · Atherosclerosis
  2. Time-averaged low-density lipoprotein cholesterol lowering with evolocumab: Pooled analysis of phase 2 trials.
    Schludi B, Giugliano RP, Sabatine MS, et al. · J Clin Lipidol · 2022 · Trial result
    PubMed: PMID 35760720 · NCT05976893 · Atherosclerosis
  3. Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease.
    O'Donoghue ML, Giugliano RP, Wiviott SD, et al. · Circulation · 2022 · Trial result
    PubMed: PMID 36031810 · NCT05976893 · Atherosclerosis
  4. Cancer treatment and survivorship statistics, 2022.
    Miller KD, Nogueira L, Devasia T, et al. · CA Cancer J Clin · 2022 · Trial result
    PubMed: PMID 35736631 · NCT05976893 · Atherosclerosis
  5. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).
    Lyon AR, López-Fernández T, Couch LS, et al. · Eur Heart J · 2022 · Trial result
    PubMed: PMID 36017568 · NCT05976893 · Atherosclerosis
  6. PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations.
    Hao Q, Aertgeerts B, Guyatt G, et al. · BMJ · 2022 · Trial result
    PubMed: PMID 35508320 · NCT05976893 · Atherosclerosis
  7. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2022.
    American Diabetes Association Professional Practice Committee · Diabetes Care · 2022 · Trial result
    PubMed: PMID 34964815 · NCT05976893 · Atherosclerosis
  8. Inclisiran: A Novel Agent for Lowering Apolipoprotein B-containing Lipoproteins.
    Warden BA, Duell PB · J Cardiovasc Pharmacol · 2022 · Derived
    PubMed: PMID 33990512 · NCT03060577 (ORION-3) · Atherosclerosis
  9. The Trajectory of Lipoprotein(a) During the Peri- and Early Postinfarction Period and the Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition.
    Vavuranakis MA, Jones SR, Ziogos E, et al. · Am J Cardiol · 2022 · Derived
    PubMed: PMID 35314069 · NCT04082442 (EVACS II) · Acute Coronary Syndrome
  10. Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction.
    Nicholls SJ, Kataoka Y, Nissen SE, et al. · JACC Cardiovasc Imaging · 2022 · Derived
    PubMed: PMID 35431172 · NCT03570697 · Coronary Artery Disease
  11. In-hospital initiation of PCSK9 inhibitor and short-term lipid control in patients with acute myocardial infarction.
    Lou B, Liu H, Luo Y, et al. · Lipids Health Dis · 2022 · Derived
    PubMed: PMID 36280861 · NCT05184530 · Coronary Disease
  12. Efficacy and Safety of Long-Term Evolocumab Use Among Asian Subjects　- A Subgroup Analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial.
    Keech AC, Oyama K, Sever PS, et al. · Circ J · 2022 · Derived
    PubMed: PMID 33980763 · NCT01764633 (FOURIER) · Hypercholesterolemia
  13. Association between causative mutations and response to PCSK9 inhibitor therapy in subjects with familial hypercholesterolemia: A single center real-world study.
    Iannuzzo G, Buonaiuto A, Calcaterra I, et al. · Nutr Metab Cardiovasc Dis · 2022 · Derived
    PubMed: PMID 34991937 · NCT04313270 · Hyperlipoproteinemia Type II
  14. Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction: A Prespecified Secondary Analysis From the FOURIER Trial.
    Gencer B, Mach F, Murphy SA, et al. · JAMA Cardiol · 2022 · Derived
    PubMed: PMID 32432684 · NCT01764633 (FOURIER) · Hypercholesterolemia
  15. Effect of Evolocumab in Patients With Prior Percutaneous Coronary Intervention.
    Furtado RHM, Fagundes AA, Oyama K, et al. · Circ Cardiovasc Interv · 2022 · Derived
    PubMed: PMID 35209731 · NCT01764633 (FOURIER) · Hypercholesterolemia
  16. Biomarker Prediction of Complex Coronary Revascularization Procedures in the FOURIER Trial.
    Fagundes A, Morrow DA, Oyama K, et al. · J Am Coll Cardiol · 2022 · Derived
    PubMed: PMID 36007987 · NCT01764633 (FOURIER) · Hypercholesterolemia
  17. Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy: Secondary Analysis From the FOURIER Randomized Clinical Trial.
    Deedwania P, Murphy SA, Scheen A, et al. · JAMA Cardiol · 2022 · Derived
    PubMed: PMID 32785614 · NCT01764633 (FOURIER) · Hypercholesterolemia
  18. Evolocumab in patients with homozygous familial hypercholesterolemia in India.
    Bansal S, Ruzza A, Sawhney J, et al. · J Clin Lipidol · 2022 · Derived
    PubMed: PMID 34750081 · NCT03403374 (RAMAN) · Hypercholesterolemia
  19. Paediatric patients with heterozygous familial hypercholesterolaemia treated with evolocumab for 80 weeks (HAUSER-OLE): a single-arm, multicentre, open-label extension of HAUSER-RCT.
    Santos RD, Ruzza A, Hovingh GK, et al. · Lancet Diabetes Endocrinol · 2022 · Background
    PubMed: PMID 36075246 · NCT02624869 (HAUSER-OLE) · Hypercholesterolemia
  20. Assessing the impact of PCSK9 inhibition on coronary plaque phenotype with optical coherence tomography: rationale and design of the randomized, placebo-controlled HUYGENS study.
    Nicholls SJ, Nissen SE, Prati F, et al. · Cardiovasc Diagn Ther · 2022 · Background
    PubMed: PMID 33708484 · NCT03570697 · Coronary Artery Disease
  21. Cognitive function with evolocumab in pediatric heterozygous familial hypercholesterolemia.
    Gaudet D, Ruzza A, Bridges I, et al. · J Clin Lipidol · 2022 · Background
    PubMed: PMID 36210291 · NCT02392559 (HAUSER-RCT) · Hypercholesterolemia
  22. Long-term effects of evolocumab in participants with HIV and dyslipidemia: results from the open-label extension period.
    Boccara F, Caramelli B, Calmy A, et al. · AIDS · 2022 · Background
    PubMed: PMID 35025817 · NCT02833844 · Hyperlipidemias

2021 (23 papers)

  1. Effects of Evolocumab on the Postprandial Kinetics of Apo (Apolipoprotein) B100- and B48-Containing Lipoproteins in Subjects With Type 2 Diabetes.
    Taskinen MR, Björnson E, Kahri J, et al. · Arterioscler Thromb Vasc Biol · 2021 · Trial result
    PubMed: PMID 33356392 · NCT02948777 · Cardiovascular Diseases
  2. Impact of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab on the postprandial responses of triglyceride-rich lipoproteins in type II diabetic subjects.
    Taskinen MR, Björnson E, Andersson L, et al. · J Clin Lipidol · 2021 · Trial result
    PubMed: PMID 31917184 · NCT02948777 · Cardiovascular Diseases
  3. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.
    Mach F, Baigent C, Catapano AL, et al. · Eur Heart J · 2021 · Trial result
    PubMed: PMID 31504418 · NCT05976893 · Atherosclerosis
  4. [Chinese expert consensus on lipid management in patients with malignancy].
    Integrative Cardio-Oncology Society of China Anti-Cancer Association · Zhonghua Zhong Liu Za Zhi · 2021 · Trial result
    PubMed: PMID 34695894 · NCT05976893 · Atherosclerosis
  5. Lipid goal attainment in post-acute coronary syndrome patients in China: Results from the 6-month real-world dyslipidemia international study II.
    Gong Y, Li X, Ma X, et al. · Clin Cardiol · 2021 · Trial result
    PubMed: PMID 34651329 · NCT05976893 · Atherosclerosis
  6. Evaluation and management of cancer patients presenting with acute cardiovascular disease: a Consensus Document of the Acute CardioVascular Care (ACVC) association and the ESC council of Cardio-Oncology-Part 1: acute coronary syndromes and acute pericardial diseases.
    Gevaert SA, Halvorsen S, Sinnaeve PR, et al. · Eur Heart J Acute Cardiovasc Care · 2021 · Trial result
    PubMed: PMID 34453829 · NCT05976893 · Atherosclerosis
  7. Acute myocardial infarction treatments and outcomes in 6.5 million patients with a current or historical diagnosis of cancer in the USA.
    Bharadwaj A, Potts J, Mohamed MO, et al. · Eur Heart J · 2021 · Trial result
    PubMed: PMID 31800032 · NCT05976893 · Atherosclerosis
  8. CARotid plaqUe StabilizatiOn and regression with evolocumab: Rationale and design of the CARUSO study.
    Aranzulla TC, Piazza S, Ricotti A, et al. · Catheter Cardiovasc Interv · 2021 · Trial result
    PubMed: PMID 33893754 · NCT04730973 (CARUSO) · Carotid Artery Diseases
  9. Metabolic effects of PCSK9 inhibition with Evolocumab in subjects with elevated Lp(a).
    Zhang X, Stiekema LCA, Stroes ESG, et al. · Lipids Health Dis · 2021 · Derived
    PubMed: PMID 32393252 · NCT02729025 (ANITSCHKOW) · Hyperlipidemias
  10. Effect of Evolocumab on Type and Size of Subsequent Myocardial Infarction: A Prespecified Analysis of the FOURIER Randomized Clinical Trial.
    Wiviott SD, Giugliano RP, Morrow DA, et al. · JAMA Cardiol · 2021 · Derived
    PubMed: PMID 32347885 · NCT01764633 (FOURIER) · Hypercholesterolemia
  11. Potent lipoprotein(a) lowering following apolipoprotein(a) antisense treatment reduces the pro-inflammatory activation of circulating monocytes in patients with elevated lipoprotein(a).
    Stiekema LCA, Prange KHM, Hoogeveen RM, et al. · Eur Heart J · 2021 · Derived
    PubMed: PMID 32268367 · NCT02729025 (ANITSCHKOW) · Hyperlipidemias
  12. Effect of evolocumab on acute arterial events across all vascular territories : results from the FOURIER trial.
    Oyama K, Giugliano RP, Tang M, et al. · Eur Heart J · 2021 · Derived
    PubMed: PMID 34537830 · NCT01764633 (FOURIER) · Hypercholesterolemia
  13. Effect of Evolocumab on Complex Coronary Disease Requiring Revascularization.
    Oyama K, Furtado RHM, Fagundes A, et al. · J Am Coll Cardiol · 2021 · Derived
    PubMed: PMID 33197560 · NCT01764633 (FOURIER) · Hypercholesterolemia
  14. Evolocumab, a PCSK9-Monoclonal Antibody, Rapidly Reverses Coronary Artery Endothelial Dysfunction in People Living With HIV and People With Dyslipidemia.
    Leucker TM, Gerstenblith G, Schär M, et al. · J Am Heart Assoc · 2021 · Derived
    PubMed: PMID 32674634 · NCT03500302 (EVOLVE) · Coronary Artery Disease
  15. Evolocumab vs. Ezetimibe in Statin-Intolerant Hyperlipidemic Japanese Patients: Phase 3 GAUSS-4 Trial.
    Koba S, Inoue I, Cyrille M, et al. · J Atheroscler Thromb · 2021 · Derived
    PubMed: PMID 31748467 · NCT02634580 (GAUSS-4) · Hypercholesterolemia
  16. Effects of Evolocumab Added to Moderate-Intensity Statin Therapy in Chinese Patients With Acute Coronary Syndrome: The EMSIACS Trial Study Protocol.
    Gao J, Liu JY, Lu PJ, et al. · Front Physiol · 2021 · Derived
    PubMed: PMID 34887772 · NCT04100434 (EMSIACS) · Acute Coronary Syndrome
  17. Cholesterol lowering with EVOLocumab to prevent cardiac allograft Vasculopathy in De-novo heart transplant recipients: Design of the randomized controlled EVOLVD trial.
    Broch K, Gude E, Karason K, et al. · Clin Transplant · 2021 · Derived
    PubMed: PMID 32445429 · NCT03734211 (EVOLVD) · Vascular Diseases
  18. An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial.
    Bergmark BA, O'Donoghue ML, Murphy SA, et al. · JAMA Cardiol · 2021 · Derived
    PubMed: PMID 32347887 · NCT01764633 (FOURIER) · Hypercholesterolemia
  19. Percutaneous Coronary Intervention for Vulnerable Coronary Atherosclerotic Plaque.
    Stone GW, Maehara A, Ali ZA, et al. · J Am Coll Cardiol · 2021 · Background
    PubMed: PMID 33069847 · NCT04719221 · Acute Coronary Syndrome
  20. Lipoprotein(a) in atherosclerosis: from pathophysiology to clinical relevance and treatment options.
    Rehberger Likozar A, Zavrtanik M, Šebeštjen M, et al. · Ann Med · 2021 · Background
    PubMed: PMID 32453609 · NCT04613167 (GEBI) · Dyslipidemias
  21. Ranson score to stratify severity in Acute Pancreatitis remains valid - Old is gold.
    Ong Y, Shelat VG · Expert Rev Gastroenterol Hepatol · 2021 · Background
    PubMed: PMID 33944648 · NCT07388420
  22. Effects of Evolocumab on Low-Density Lipoprotein Cholesterol, Non-High Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a) by Race and Ethnicity: A Meta-Analysis of Individual Participant Data From Double-Blind and Open-Label Extension Studies.
    Daviglus ML, Ferdinand KC, López JAG, et al. · J Am Heart Assoc · 2021 · Background
    PubMed: PMID 33325247 · NCT01516879 (DESCARTES) · Hypercholesterolemia
  23. Evolocumab in HIV-Infected Patients With Dyslipidemia: Primary Results of the Randomized, Double-Blind BEIJERINCK Study.
    Boccara F, Kumar PN, Caramelli B, et al. · J Am Coll Cardiol · 2021 · Background
    PubMed: PMID 32234462 · NCT02833844 · Hyperlipidemias

2020 (29 papers)

  1. [China cholesterol education program (CCEP) expert advice for the management of dyslipidaemias to reduce cardiovascular risk (2019)].
    China Cholesterol Education Program (CCEP) Working Committee, Atherosclerosis Thrombosis Prevention and Control Subcommittee of Chinese International Exchange and Promotion Association for Medical and Healthcare, Cardiovascular Disease Subcommittee of China Association of Gerontology and Geriatrics, et al. · Zhonghua Nei Ke Za Zhi · 2020 · Trial result
    PubMed: PMID 31887831 · NCT05976893 · Atherosclerosis
  2. Investigation of human apoB48 metabolism using a new, integrated non-steady-state model of apoB48 and apoB100 kinetics.
    Björnson E, Packard CJ, Adiels M, et al. · J Intern Med · 2020 · Trial result
    PubMed: PMID 30779243 · NCT02948777 · Cardiovascular Diseases
  3. [Chinese expert consensus on lipid management of very high-risk atherosclerotic cardiovascular disease patients].
    Atherosclerosis and Coronary Heart Disease Working Group of Chinese Society of Cardiology, Editorial Board of Chinese Journal of Cardiology · Zhonghua Xin Xue Guan Bing Za Zhi · 2020 · Trial result
    PubMed: PMID 32370478 · NCT05976893 · Atherosclerosis
  4. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.
    Schmidt AF, Carter JL, Pearce LS, et al. · Cochrane Database Syst Rev · 2020 · Derived
    PubMed: PMID 33078867 · NCT01813422 (GLAGOV) · Hypercholesterolemia
  5. Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study.
    Rosenson RS, Daviglus ML, Handelsman Y, et al. · Diabetologia · 2020 · Derived
    PubMed: PMID 30953107 · NCT02739984 (BANTING) · Hypercholesterolemia
  6. Interindividual Variation in Low-Density Lipoprotein Cholesterol Level Reduction With Evolocumab: An Analysis of FOURIER Trial Data.
    Qamar A, Giugliano RP, Keech AC, et al. · JAMA Cardiol · 2020 · Derived
    PubMed: PMID 30540337 · NCT01764633 (FOURIER) · Hypercholesterolemia
  7. Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease: A Prespecified Analysis From the FOURIER Trial.
    Murphy SA, Pedersen TR, Gaciong ZA, et al. · JAMA Cardiol · 2020 · Derived
    PubMed: PMID 31116355 · NCT01764633 (FOURIER) · Hypercholesterolemia
  8. Evolocumab for Early Reduction of LDL Cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS).
    Koskinas KC, Windecker S, Pedrazzini G, et al. · J Am Coll Cardiol · 2020 · Derived
    PubMed: PMID 31479722 · NCT03287609 (EVOPACS) · Acute Coronary Syndrome
  9. Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis.
    Giugliano RP, Pedersen TR, Saver JL, et al. · Stroke · 2020 · Derived
    PubMed: PMID 32312223 · NCT01764633 (FOURIER) · Hypercholesterolemia
  10. Randomized study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin: Pre-specified analysis of the Chinese population from the BERSON clinical trial.
    Chen Y, Yuan Z, Lu J, et al. · Diabetes Obes Metab · 2020 · Derived
    PubMed: PMID 30851062 · NCT02662569 (BERSON) · Hyperlipidemias
  11. Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial.
    Charytan DM, Sabatine MS, Pedersen TR, et al. · J Am Coll Cardiol · 2020 · Derived
    PubMed: PMID 31196453 · NCT01764633 (FOURIER) · Hypercholesterolemia
  12. Lipoprotein(a) Particle Production as a Determinant of Plasma Lipoprotein(a) Concentration Across Varying Apolipoprotein(a) Isoform Sizes and Background Cholesterol-Lowering Therapy.
    Chan DC, Watts GF, Coll B, et al. · J Am Heart Assoc · 2020 · Derived
    PubMed: PMID 30897995 · NCT02189837 (FLOREY) · Hypercholesterolemia
  13. Effect of Evolocumab on Non-High-Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a): A Pooled Analysis of Phase 2 and Phase 3 Studies.
    Toth PP, Jones SR, Monsalvo ML, et al. · J Am Heart Assoc · 2020 · Background
    PubMed: PMID 32114889 · NCT01763905 (GAUSS-2) · Hypercholesterolemia
  14. Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment.
    Stiekema LCA, Stroes ESG, Verweij SL, et al. · Eur Heart J · 2020 · Background
    PubMed: PMID 30561610 · NCT02729025 (ANITSCHKOW) · Hyperlipidemias
  15. Relationship Between Low-Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab.
    Shapiro MD, Minnier J, Tavori H, et al. · J Am Heart Assoc · 2020 · Background
    PubMed: PMID 30755061 · NCT01763827 (MENDEL-2) · Hypercholesterolemia
  16. Long-Term Evolocumab in Patients With Familial Hypercholesterolemia.
    Santos RD, Stein EA, Hovingh GK, et al. · J Am Coll Cardiol · 2020 · Background
    PubMed: PMID 32057369 · NCT01624142 (TAUSSIG) · Hypercholesterolemia
  17. Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia.
    Santos RD, Ruzza A, Hovingh GK, et al. · N Engl J Med · 2020 · Background
    PubMed: PMID 32865373 · NCT02392559 (HAUSER-RCT) · Hypercholesterolemia
  18. Biology, pathophysiology and current therapies that affect lipoprotein (a) levels.
    Rawther T, Tabet F · J Mol Cell Cardiol · 2020 · Background
    PubMed: PMID 30986377 · NCT04613167 (GEBI) · Dyslipidemias
  19. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2020 Aug
    · 2020 · Background
    PubMed: PMID 33355725 · NCT03570697 · Coronary Artery Disease
  20. 2018 ESC/EACTS Guidelines on myocardial revascularization.
    Neumann FJ, Sousa-Uva M, Ahlsson A, et al. · Eur Heart J · 2020 · Background
    PubMed: PMID 30165437 · NCT04338165 (MICROPROTECT) · Atherosclerosis
  21. Effects of Evolocumab on the ApoA1 Remnant Ratio: A Pooled Analysis of Phase 3 Studies.
    May HT, Muhlestein JB, Ma Y, et al. · Cardiol Ther · 2020 · Background
    PubMed: PMID 30852766 · NCT01763866 (LAPLACE-2) · Hypercholesterolemia
  22. Fractional turnover of apolipoprotein(a) and apolipoprotein B-100 within plasma lipoprotein(a) particles in statin-treated patients with elevated and normal Lp(a) concentration.
    Ma L, Chan DC, Ooi EMM, et al. · Metabolism · 2020 · Background
    PubMed: PMID 30995439 · NCT04613167 (GEBI) · Dyslipidemias
  23. Elevated triglycerides on admission positively correlate with the severity of hypertriglyceridaemic pancreatitis.
    Lu Z, Zhang G, Guo F, et al. · Int J Clin Pract · 2020 · Background
    PubMed: PMID 31799779 · NCT07388420
  24. Influence of Renal Function on Evolocumab Exposure, Pharmacodynamics, and Safety.
    Lee E, Gibbs JP, Emery MG, et al. · Clin Pharmacol Drug Dev · 2020 · Background
    PubMed: PMID 30676701 · NCT02275156 · Hyperlipidemias
  25. Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia.
    Koren MJ, Sabatine MS, Giugliano RP, et al. · J Am Coll Cardiol · 2020 · Background
    PubMed: PMID 31648705 · NCT01439880 (OSLER) · Hypercholesterolemia
  26. Long-Term Treatment With Evolocumab Among Japanese Patients　- Final Report of the OSLER Open-Label Extension Studies.
    Hirayama A, Yamashita S, Ruzza A, et al. · Circ J · 2020 · Background
    PubMed: PMID 30930429 · NCT01439880 (OSLER) · Hypercholesterolemia
  27. Updated Cost-effectiveness Analysis of Evolocumab in Patients With Very High-risk Atherosclerotic Cardiovascular Disease.
    Fonarow GC, van Hout B, Villa G, et al. · JAMA Cardiol · 2020 · Background
    PubMed: PMID 31166576 · NCT01764633 (FOURIER) · Hypercholesterolemia
  28. Evolocumab treatment in patients with HIV and hypercholesterolemia/mixed dyslipidemia: BEIJERINCK study design and baseline characteristics.
    Boccara F, Kumar P, Caramelli B, et al. · Am Heart J · 2020 · Background
    PubMed: PMID 31841795 · NCT02833844 · Hyperlipidemias
  29. Effect of evolocumab on lipoprotein apheresis requirement and lipid levels: Results of the randomized, controlled, open-label DE LAVAL study.
    Baum SJ, Sampietro T, Datta D, et al. · J Clin Lipidol · 2020 · Background
    PubMed: PMID 31759938 · NCT02585895 · Hypercholesterolemia

2019 (23 papers)

  1. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.
    Zhou M, Wang H, Zeng X, et al. · Lancet · 2019 · Trial result
    PubMed: PMID 31248666 · NCT05976893 · Atherosclerosis
  2. Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER.
    Sabatine MS, De Ferrari GM, Giugliano RP, et al. · Circulation · 2019 · Derived
    PubMed: PMID 29626068 · NCT01764633 (FOURIER) · Hypercholesterolemia
  3. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk.
    O'Donoghue ML, Fazio S, Giugliano RP, et al. · Circulation · 2019 · Derived
    PubMed: PMID 30586750 · NCT01764633 (FOURIER) · Hypercholesterolemia
  4. Comparison of Low-Density Lipoprotein Cholesterol Assessment by Martin/Hopkins Estimation, Friedewald Estimation, and Preparative Ultracentrifugation: Insights From the FOURIER Trial.
    Martin SS, Giugliano RP, Murphy SA, et al. · JAMA Cardiol · 2019 · Derived
    PubMed: PMID 29898218 · NCT01764633 (FOURIER) · Hypercholesterolemia
  5. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk).
    Bonaca MP, Nault P, Giugliano RP, et al. · Circulation · 2019 · Derived
    PubMed: PMID 29133605 · NCT01764633 (FOURIER) · Hypercholesterolemia
  6. Inflammatory and Cholesterol Risk in the FOURIER Trial.
    Bohula EA, Giugliano RP, Leiter LA, et al. · Circulation · 2019 · Derived
    PubMed: PMID 29530884 · NCT01764633 (FOURIER) · Hypercholesterolemia
  7. Evolocumab: Considerations for the Management of Hyperlipidemia.
    Wiggins BS, Senfield J, Kassahun H, et al. · Curr Atheroscler Rep · 2019 · Background
    PubMed: PMID 29511875 · NCT07388420
  8. Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics.
    Watts GF, Chan DC, Somaratne R, et al. · Eur Heart J · 2019 · Background
    PubMed: PMID 29566128 · NCT02189837 (FLOREY) · Hypercholesterolemia
  9. Comparison of LDL-C Reduction Using Different Evolocumab Doses and Intervals: Biological Insights and Treatment Implications.
    Wasserman SM, Sabatine MS, Koren MJ, et al. · J Cardiovasc Pharmacol Ther · 2019 · Background
    PubMed: PMID 29768954 · NCT01763866 (LAPLACE-2) · Hypercholesterolemia
  10. Effect of Evolocumab on Lipoprotein Particles.
    Toth PP, Sattar N, Blom DJ, et al. · Am J Cardiol · 2019 · Background
    PubMed: PMID 29221604 · NCT01516879 (DESCARTES) · Hypercholesterolemia
  11. Lipoprotein(a) as an Old and New Causal Risk Factor of Atherosclerotic Cardiovascular Disease.
    Tada H, Takamura M, Kawashiri MA, et al. · J Atheroscler Thromb · 2019 · Background
    PubMed: PMID 31061262 · NCT04613167 (GEBI) · Dyslipidemias
  12. Effect of Evolocumab on Coronary Plaque Composition.
    Nicholls SJ, Puri R, Anderson T, et al. · J Am Coll Cardiol · 2019 · Background
    PubMed: PMID 30336824 · NCT01813422 (GLAGOV) · Hypercholesterolemia
  13. 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia.
    Landmesser U, Chapman MJ, Stock JK, et al. · Eur Heart J · 2019 · Background
    PubMed: PMID 29045644 · NCT04338165 (MICROPROTECT) · Atherosclerosis
  14. Population pharmacokinetics and exposure-response modeling and simulation for evolocumab in healthy volunteers and patients with hypercholesterolemia.
    Kuchimanchi M, Grover A, Emery MG, et al. · J Pharmacokinet Pharmacodyn · 2019 · Background
    PubMed: PMID 29736889 · NCT01516879 (DESCARTES) · Hypercholesterolemia
  15. Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study.
    Koren MJ, Sabatine MS, Giugliano RP, et al. · JAMA Cardiol · 2019 · Background
    PubMed: PMID 28291870 · NCT01439880 (OSLER) · Hypercholesterolemia
  16. Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor.
    Kasichayanula S, Grover A, Emery MG, et al. · Clin Pharmacokinet · 2019 · Background
    PubMed: PMID 29353350 · NCT02275156 · Hyperlipidemias
  17. Pleiotropic Anti-atherosclerotic Effects of PCSK9 InhibitorsFrom Molecular Biology to Clinical Translation.
    Karagiannis AD, Liu M, Toth PP, et al. · Curr Atheroscler Rep · 2019 · Background
    PubMed: PMID 29525934 · NCT04338165 (MICROPROTECT) · Atherosclerosis
  18. Lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 inhibitors.
    Julius U, Tselmin S, Schatz U, et al. · Clin Res Cardiol Suppl · 2019 · Background
    PubMed: PMID 30838555 · NCT04613167 (GEBI) · Dyslipidemias
  19. A transcriptomic model to predict increase in fibrous cap thickness in response to high-dose statin treatment: Validation by serial intracoronary OCT imaging.
    Johnson KW, Glicksberg BS, Shameer K, et al. · EBioMedicine · 2019 · Background
    PubMed: PMID 31126891 · NCT04710368 (YELLOW III) · Coronary Artery Disease
  20. Efficacy, safety, and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: Rationale and design of the HAUSER-RCT study.
    Gaudet D, Langslet G, Gidding SS, et al. · J Clin Lipidol · 2019 · Background
    PubMed: PMID 30318065 · NCT02392559 (HAUSER-RCT) · Hypercholesterolemia
  21. Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease.
    Fonarow GC, Keech AC, Pedersen TR, et al. · JAMA Cardiol · 2019 · Background
    PubMed: PMID 28832867 · NCT01764633 (FOURIER) · Hypercholesterolemia
  22. Persistent Safety and Efficacy of Evolocumab in Patients with Statin Intolerance: a Subset Analysis of the OSLER Open-Label Extension Studies.
    Cho L, Dent R, Stroes ESG, et al. · Cardiovasc Drugs Ther · 2019 · Background
    PubMed: PMID 30073585 · NCT01984424 (GAUSS-3) · Hypercholesterolemia
  23. Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism.
    Chan DC, Watts GF, Somaratne R, et al. · Arterioscler Thromb Vasc Biol · 2019 · Background
    PubMed: PMID 29880491 · NCT02189837 (FLOREY) · Hypercholesterolemia

2018 (14 papers)

  1. Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries.
    Zeng H, Chen W, Zheng R, et al. · Lancet Glob Health · 2018 · Trial result
    PubMed: PMID 29653628 · NCT05976893 · Atherosclerosis
  2. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
    Schwartz GG, Steg PG, Szarek M, et al. · N Engl J Med · 2018 · Trial result
    PubMed: PMID 30403574 · NCT05976893 · Atherosclerosis
  3. Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemia.
    Hovingh GK, Raal FJ, Dent R, et al. · J Clin Lipidol · 2018 · Trial result
    PubMed: PMID 29066265 · NCT01854918 (OSLER-2) · Hypercholesterolemia
  4. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial.
    Sabatine MS, Leiter LA, Wiviott SD, et al. · Lancet Diabetes Endocrinol · 2018 · Derived
    PubMed: PMID 28927706 · NCT01764633 (FOURIER) · Hypercholesterolemia
  5. Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors: Shaping the future after the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) trial.
    Katsiki N, Athyros VG, Mikhailidis DP, et al. · Metabolism · 2018 · Derived
    PubMed: PMID 28477848 · NCT03080935 · Dyslipidemias
  6. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial.
    Giugliano RP, Pedersen TR, Park JG, et al. · Lancet · 2018 · Derived
    PubMed: PMID 28859947 · NCT01764633 (FOURIER) · Hypercholesterolemia
  7. 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents.
    Writing Committee, Lloyd-Jones DM, Morris PB, et al. · J Am Coll Cardiol · 2018 · Background
    PubMed: PMID 27046161 · NCT03331666 · Hypercholesterolemia
  8. Consistent LDL-C response with evolocumab among patient subgroups in PROFICIO: A pooled analysis of 3146 patients from phase 3 studies.
    Stroes E, Robinson JG, Raal FJ, et al. · Clin Cardiol · 2018 · Background
    PubMed: PMID 30120772 · NCT01763905 (GAUSS-2) · Hypercholesterolemia
  9. Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study.
    Raal FJ, Hovingh GK, Blom D, et al. · Lancet Diabetes Endocrinol · 2018 · Background
    PubMed: PMID 28215937 · NCT01624142 (TAUSSIG) · Hypercholesterolemia
  10. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis.
    Pinkosky SL, Newton RS, Day EA, et al. · Nat Commun · 2018 · Background
    PubMed: PMID 27892461 · NCT03193047 · Hypercholesterolemia
  11. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR).
    Piepoli MF, Hoes AW, Agewall S, et al. · Eur Heart J · 2018 · Background
    PubMed: PMID 27222591 · NCT04338165 (MICROPROTECT) · Atherosclerosis
  12. One-Year Efficacy and Safety of Evolocumab in Japanese Patients　- A Pooled Analysis From the Open-Label Extension OSLER Studies.
    Hirayama A, Yamashita S, Inomata H, et al. · Circ J · 2018 · Background
    PubMed: PMID 28367845 · NCT01652703 (AMG145) · Hypercholesterolemia
  13. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias.
    Catapano AL, Graham I, De Backer G, et al. · Eur Heart J · 2018 · Background
    PubMed: PMID 27567407 · NCT04338165 (MICROPROTECT) · Atherosclerosis
  14. Practical Considerations for the Use of Subcutaneous Treatment in the Management of Dyslipidaemia.
    Boccara F, Dent R, Ruilope L, et al. · Adv Ther · 2018 · Background
    PubMed: PMID 28717862 · NCT01879319 · Hypercholesterolemia

2017 (18 papers)

  1. Effect of the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Evolocumab on Glycemia, Body Weight, and New-Onset Diabetes Mellitus.
    Sattar N, Toth PP, Blom DJ, et al. · Am J Cardiol · 2017 · Trial result
    PubMed: PMID 28844508 · NCT01854918 (OSLER-2) · Hypercholesterolemia
  2. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
    Sabatine MS, Giugliano RP, Keech AC, et al. · N Engl J Med · 2017 · Trial result
    PubMed: PMID 28304224 · NCT03287609 (EVOPACS) · Acute Coronary Syndrome
  3. Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies for Acute Coronary Syndrome: A Narrative Review.
    Navarese EP, Kolodziejczak M, Kereiakes DJ, et al. · Ann Intern Med · 2017 · Trial result
    PubMed: PMID 26999484 · NCT03287609 (EVOPACS) · Acute Coronary Syndrome
  4. The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis.
    Lipinski MJ, Benedetto U, Escarcega RO, et al. · Eur Heart J · 2017 · Trial result
    PubMed: PMID 26578202 · NCT03287609 (EVOPACS) · Acute Coronary Syndrome
  5. Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV).
    Puri R, Nissen SE, Somaratne R, et al. · Am Heart J · 2017 · Derived
    PubMed: PMID 27264224 · NCT01813422 (GLAGOV) · Hypercholesterolemia
  6. Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism.
    Watts GF, Chan DC, Dent R, et al. · Circulation · 2017 · Background
    PubMed: PMID 27941065 · NCT02189837 (FLOREY) · Hypercholesterolemia
  7. A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies.
    Tsimikas S · J Am Coll Cardiol · 2017 · Background
    PubMed: PMID 28183512 · NCT04613167 (GEBI) · Dyslipidemias
  8. Pooled Safety Analysis of Evolocumab in Over 6000 Patients From Double-Blind and Open-Label Extension Studies.
    Toth PP, Descamps O, Genest J, et al. · Circulation · 2017 · Background
    PubMed: PMID 28249876 · NCT01849497 · Hypercholesterolemia
  9. Lipopolysaccharide Is Cleared from the Circulation by Hepatocytes via the Low Density Lipoprotein Receptor.
    Topchiy E, Cirstea M, Kong HJ, et al. · PLoS One · 2017 · Background
    PubMed: PMID 27171436 · NCT03869073 (PLEASe) · Infections
  10. Two-year follow-up of patients with septic shock presenting with low HDL: the effect upon acute kidney injury, death and estimated glomerular filtration rate.
    Roveran Genga K, Lo C, Cirstea M, et al. · J Intern Med · 2017 · Background
    PubMed: PMID 28317295 · NCT03869073 (PLEASe) · Infections
  11. Soluble VE-cadherin in metastatic breast cancer: an independent prognostic factor for both progression-free survival and overall survival.
    Rochefort P, Chabaud S, Pierga JY, et al. · Br J Cancer · 2017 · Background
    PubMed: PMID 28056463 · NCT04338165 (MICROPROTECT) · Atherosclerosis
  12. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.
    Nicholls SJ, Puri R, Anderson T, et al. · JAMA · 2017 · Background
    PubMed: PMID 27846344 · NCT01813422 (GLAGOV) · Hypercholesterolemia
  13. Intracoronary Imaging, Cholesterol Efflux, and Transcriptomes After Intensive Statin Treatment: The YELLOW II Study.
    Kini AS, Vengrenyuk Y, Shameer K, et al. · J Am Coll Cardiol · 2017 · Background
    PubMed: PMID 27989886 · NCT04719221 · Acute Coronary Syndrome
  14. Design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy-A cognitive study of patients enrolled in the FOURIER trial.
    Giugliano RP, Mach F, Zavitz K, et al. · Clin Cardiol · 2017 · Background
    PubMed: PMID 28207168 · NCT02207634 (EBBINGHAUS) · Hypercholesterolemia
  15. Cognitive Function in a Randomized Trial of Evolocumab.
    Giugliano RP, Mach F, Zavitz K, et al. · N Engl J Med · 2017 · Background
    PubMed: PMID 28813214 · NCT02207634 (EBBINGHAUS) · Hypercholesterolemia
  16. Decreased high-density lipoprotein cholesterol level is an early prognostic marker for organ dysfunction and death in patients with suspected sepsis.
    Cirstea M, Walley KR, Russell JA, et al. · J Crit Care · 2017 · Background
    PubMed: PMID 28013095 · NCT03869073 (PLEASe) · Infections
  17. Evaluation of the efficacy, safety and glycaemic effects of evolocumab (AMG 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome.
    Blom DJ, Koren MJ, Roth E, et al. · Diabetes Obes Metab · 2017 · Background
    PubMed: PMID 27619750 · NCT01516879 (DESCARTES) · Hypercholesterolemia
  18. 2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult.
    Anderson TJ, Grégoire J, Pearson GJ, et al. · Can J Cardiol · 2017 · Background
    PubMed: PMID 27712954 · NCT04397653 · Hypercholesterolemia

2016 (7 papers)

  1. Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial.
    Nissen SE, Stroes E, Dent-Acosta RE, et al. · JAMA · 2016 · Derived
    PubMed: PMID 27039291 · NCT01984424 (GAUSS-3) · Hypercholesterolemia
  2. Evolocumab lowers LDL-C safely and effectively when self-administered in the at-home setting.
    Dent R, Joshi R, Stephen Djedjos C, et al. · Springerplus · 2016 · Derived
    PubMed: PMID 27066336 · NCT01849497 · Hypercholesterolemia
  3. Plaque Characterization to Inform the Prediction and Prevention of Periprocedural Myocardial Infarction During Percutaneous Coronary Intervention: The CANARY Trial (Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow).
    Stone GW, Maehara A, Muller JE, et al. · JACC Cardiovasc Interv · 2016 · Background
    PubMed: PMID 26003018 · NCT04719221 · Acute Coronary Syndrome
  4. Near-Infrared Spectroscopy Enhances Intravascular Ultrasound Assessment of Vulnerable Coronary Plaque: A Combined Pathological and In Vivo Study.
    Puri R, Madder RD, Madden SP, et al. · Arterioscler Thromb Vasc Biol · 2016 · Background
    PubMed: PMID 26338299 · NCT04719221 · Acute Coronary Syndrome
  5. Endothelial nitric oxide synthase: From biochemistry and gene structure to clinical implications of NOS3 polymorphisms.
    Oliveira-Paula GH, Lacchini R, Tanus-Santos JE, et al. · Gene · 2016 · Background
    PubMed: PMID 26428312 · NCT04613167 (GEBI) · Dyslipidemias
  6. Lipoprotein (a) measurements for clinical application.
    Marcovina SM, Albers JJ · J Lipid Res · 2016 · Background
    PubMed: PMID 26637278 · NCT04613167 (GEBI) · Dyslipidemias
  7. Increased Plasma PCSK9 Levels Are Associated with Reduced Endotoxin Clearance and the Development of Acute Organ Failures during Sepsis.
    Boyd JH, Fjell CD, Russell JA, et al. · J Innate Immun · 2016 · Background
    PubMed: PMID 26756586 · NCT03869073 (PLEASe) · Infections

2015 (15 papers)

  1. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.
    Sabatine MS, Giugliano RP, Wiviott SD, et al. · N Engl J Med · 2015 · Trial result
    PubMed: PMID 25773607 · NCT05976893 · Atherosclerosis
  2. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
    Cannon CP, Blazing MA, Giugliano RP, et al. · N Engl J Med · 2015 · Trial result
    PubMed: PMID 26039521 · NCT05976893 · Atherosclerosis
  3. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial.
    Raal FJ, Honarpour N, Blom DJ, et al. · Lancet · 2015 · Derived
    PubMed: PMID 25282520 · NCT01588496 (TESLA) · Hypercholesterolemia
  4. KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient.
    Wanner C, Tonelli M, Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members, et al. · Kidney Int · 2015 · Background
    PubMed: PMID 24552851 · NCT04608474 · Hypercholesterolemia
  5. PCSK9 is a critical regulator of the innate immune response and septic shock outcome.
    Walley KR, Thain KR, Russell JA, et al. · Sci Transl Med · 2015 · Background
    PubMed: PMID 25320235 · NCT03869073 (PLEASe) · Infections
  6. Global coronary flow reserve is associated with adverse cardiovascular events independently of luminal angiographic severity and modifies the effect of early revascularization.
    Taqueti VR, Hachamovitch R, Murthy VL, et al. · Circulation · 2015 · Background
    PubMed: PMID 25400060 · NCT04338165 (MICROPROTECT) · Atherosclerosis
  7. Cholesterol, inflammation and innate immunity.
    Tall AR, Yvan-Charvet L · Nat Rev Immunol · 2015 · Background
    PubMed: PMID 25614320 · NCT03829046 · Atherosclerosis
  8. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial.
    Raal FJ, Stein EA, Dufour R, et al. · Lancet · 2015 · Background
    PubMed: PMID 25282519 · NCT07388420
  9. The influence of statin therapy on platelet activity markers in hyperlipidemic patients after ischemic stroke.
    Pawelczyk M, Chmielewski H, Kaczorowska B, et al. · Arch Med Sci · 2015 · Background
    PubMed: PMID 25861297 · NCT03331666 · Hypercholesterolemia
  10. Lipoprotein (a): structure, pathophysiology and clinical implications.
    Maranhão RC, Carvalho PO, Strunz CC, et al. · Arq Bras Cardiol · 2015 · Background
    PubMed: PMID 25120086 · NCT04613167 (GEBI) · Dyslipidemias
  11. Endothelial nitric oxide synthase genotypes modulate peripheral vasodilatory properties after myocardial infarction.
    Machado-Silva W, Alfinito-Kreis R, Carvalho LS, et al. · Gene · 2015 · Background
    PubMed: PMID 26002446 · NCT04613167 (GEBI) · Dyslipidemias
  12. Pharmacodynamic effects of adjunctive high dose atorvastatin on double dose clopidogrel in patients with high on-treatment platelet reactivity depending on diabetes mellitus status.
    Leoncini M, Toso A, Maioli M, et al. · J Thromb Thrombolysis · 2015 · Background
    PubMed: PMID 23852152 · NCT03331666 · Hypercholesterolemia
  13. Hemodynamic shear stress via ROS modulates PCSK9 expression in human vascular endothelial and smooth muscle cells and along the mouse aorta.
    Ding Z, Liu S, Wang X, et al. · Antioxid Redox Signal · 2015 · Background
    PubMed: PMID 25490141 · NCT04338165 (MICROPROTECT) · Atherosclerosis
  14. Effects of Evolocumab on Vitamin E and Steroid Hormone Levels: Results From the 52-Week, Phase 3, Double-Blind, Randomized, Placebo-Controlled DESCARTES Study.
    Blom DJ, Djedjos CS, Monsalvo ML, et al. · Circ Res · 2015 · Background
    PubMed: PMID 26228031 · NCT01516879 (DESCARTES) · Hypercholesterolemia
  15. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI).
    Authors/Task Force members, Windecker S, Kolh P, et al. · Eur Heart J · 2015 · Background
    PubMed: PMID 25173339 · NCT04719221 · Acute Coronary Syndrome

2014 (18 papers)

  1. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57).
    Desai NR, Giugliano RP, Zhou J, et al. · J Am Coll Cardiol · 2014 · Trial result
    PubMed: PMID 24161333 · NCT05976893 · Atherosclerosis
  2. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia.
    Stein EA, Honarpour N, Wasserman SM, et al. · Circulation · 2014 · Derived
    PubMed: PMID 24014831 · NCT01624142 (TAUSSIG) · Hypercholesterolemia
  3. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology.
    Task Force Members, Montalescot G, Sechtem U, et al. · Eur Heart J · 2014 · Background
    PubMed: PMID 23996286 · NCT04719221 · Acute Coronary Syndrome
  4. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab.
    Stroes E, Colquhoun D, Sullivan D, et al. · J Am Coll Cardiol · 2014 · Background
    PubMed: PMID 24694531 · NCT01763905 (GAUSS-2) · Hypercholesterolemia
  5. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
    Stone NJ, Robinson JG, Lichtenstein AH, et al. · Circulation · 2014 · Background
    PubMed: PMID 24222016 · NCT03193047 · Hypercholesterolemia
  6. PCSK9: a key modulator of cardiovascular health.
    Seidah NG, Awan Z, Chrétien M, et al. · Circ Res · 2014 · Background
    PubMed: PMID 24625727 · NCT04338165 (MICROPROTECT) · Atherosclerosis
  7. Rationale and design of LAPLACE-2: a phase 3, randomized, double-blind, placebo- and ezetimibe-controlled trial evaluating the efficacy and safety of evolocumab in subjects with hypercholesterolemia on background statin therapy.
    Robinson JG, Rogers WJ, Nedergaard BS, et al. · Clin Cardiol · 2014 · Background
    PubMed: PMID 24481874 · NCT01763866 (LAPLACE-2) · Hypercholesterolemia
  8. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.
    Robinson JG, Nedergaard BS, Rogers WJ, et al. · JAMA · 2014 · Background
    PubMed: PMID 24825642 · NCT01763866 (LAPLACE-2) · Hypercholesterolemia
  9. ACC/AHA/SCAI/AMA-Convened PCPI/NCQA 2013 Performance Measures for Adults Undergoing Percutaneous Coronary Intervention: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures, the Society for Cardiovascular Angiography and Interventions, the American Medical Association-Convened Physician Consortium for Performance Improvement, and the National Committee for Quality Assurance.
    Nallamothu BK, Tommaso CL, Anderson HV, et al. · Circulation · 2014 · Background
    PubMed: PMID 24357402 · NCT04719221 · Acute Coronary Syndrome
  10. Detection by near-infrared spectroscopy of large lipid core plaques at culprit sites in patients with acute ST-segment elevation myocardial infarction.
    Madder RD, Goldstein JA, Madden SP, et al. · JACC Cardiovasc Interv · 2014 · Background
    PubMed: PMID 23871513 · NCT04719221 · Acute Coronary Syndrome
  11. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab.
    Koren MJ, Lundqvist P, Bolognese M, et al. · J Am Coll Cardiol · 2014 · Background
    PubMed: PMID 24691094 · NCT01763827 (MENDEL-2) · Hypercholesterolemia
  12. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial.
    Koren MJ, Giugliano RP, Raal FJ, et al. · Circulation · 2014 · Background
    PubMed: PMID 24255061 · NCT01439880 (OSLER) · Hypercholesterolemia
  13. Atherosclerotic intracranial arterial stenosis: risk factors, diagnosis, and treatment.
    Holmstedt CA, Turan TN, Chimowitz MI, et al. · Lancet Neurol · 2014 · Background
    PubMed: PMID 24135208 · NCT05741086 (EAST-ICAS) · Stroke
  14. An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia.
    Expert Dyslipidemia Panel, Grundy SM · J Clin Lipidol · 2014 · Background
    PubMed: PMID 24314355 · NCT04397653 · Hypercholesterolemia
  15. Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
    Derdeyn CP, Chimowitz MI, Lynn MJ, et al. · Lancet · 2014 · Background
    PubMed: PMID 24168957 · NCT05741086 (EAST-ICAS) · Stroke
  16. Design and rationale of the GAUSS-2 study trial: a double-blind, ezetimibe-controlled phase 3 study of the efficacy and tolerability of evolocumab (AMG 145) in subjects with hypercholesterolemia who are intolerant of statin therapy.
    Cho L, Rocco M, Colquhoun D, et al. · Clin Cardiol · 2014 · Background
    PubMed: PMID 24477778 · NCT01763905 (GAUSS-2) · Hypercholesterolemia
  17. Profiling inflammatory responses with microfluidic immunoblotting.
    Chang HN, Leroueil PR, Selwa K, et al. · PLoS One · 2014 · Background
    PubMed: PMID 24312374 · NCT03829046 · Atherosclerosis
  18. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.
    Blom DJ, Hala T, Bolognese M, et al. · N Engl J Med · 2014 · Background
    PubMed: PMID 24678979 · NCT01516879 (DESCARTES) · Hypercholesterolemia

2013 (15 papers)

  1. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial.
    Desai NR, Kohli P, Giugliano RP, et al. · Circulation · 2013 · Derived
    PubMed: PMID 23884353 · NCT01380730 (LAPLACE) · Hypercholesterolemia
  2. eNOS gene variants and the risk of premature myocardial infarction.
    Zigra AM, Rallidis LS, Anastasiou G, et al. · Dis Markers · 2013 · Background
    PubMed: PMID 23594558 · NCT04613167 (GEBI) · Dyslipidemias
  3. Calculation of the index of microcirculatory resistance without coronary wedge pressure measurement in the presence of epicardial stenosis.
    Yong AS, Layland J, Fearon WF, et al. · JACC Cardiovasc Interv · 2013 · Background
    PubMed: PMID 23347861 · NCT04338165 (MICROPROTECT) · Atherosclerosis
  4. Statins as antithrombotic drugs.
    Violi F, Calvieri C, Ferro D, et al. · Circulation · 2013 · Background
    PubMed: PMID 23319813 · NCT03331666 · Hypercholesterolemia
  5. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.
    Sullivan D, Olsson AG, Scott R, et al. · JAMA · 2013 · Background
    PubMed: PMID 23128163 · NCT01375764 (GAUSS) · Hypercholesterolemia
  6. Effect of statins on platelet function in patients with hyperlipidemia.
    Sikora J, Kostka B, Marczyk I, et al. · Arch Med Sci · 2013 · Background
    PubMed: PMID 24049520 · NCT03331666 · Hypercholesterolemia
  7. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
    Raal F, Scott R, Somaratne R, et al. · Circulation · 2013 · Background
    PubMed: PMID 23129602 · NCT01375751 (RUTHERFORD) · Hyperlipoproteinemia Type II
  8. The NCDR CathPCI Registry: a US national perspective on care and outcomes for percutaneous coronary intervention.
    Moussa I, Hermann A, Messenger JC, et al. · Heart · 2013 · Background
    PubMed: PMID 23322530 · NCT04719221 · Acute Coronary Syndrome
  9. Multimodality direct coronary imaging with combined near-infrared spectroscopy and intravascular ultrasound: initial US experience.
    Madder RD, Steinberg DH, Anderson RD, et al. · Catheter Cardiovasc Interv · 2013 · Background
    PubMed: PMID 22110009 · NCT04719221 · Acute Coronary Syndrome
  10. High-dose atorvastatin on the pharmacodynamic effects of double-dose clopidogrel in patients undergoing percutaneous coronary interventions: The ACHIDO (Atorvastatin and Clopidogrel HIgh DOse in stable patients with residual high platelet activity) study.
    Leoncini M, Toso A, Maioli M, et al. · JACC Cardiovasc Interv · 2013 · Background
    PubMed: PMID 23428009 · NCT03331666 · Hypercholesterolemia
  11. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study.
    Koren MJ, Scott R, Kim JB, et al. · Lancet · 2013 · Background
    PubMed: PMID 23141812 · NCT01375777 (MENDEL) · Hypercholesterolemia
  12. Changes in plaque lipid content after short-term intensive versus standard statin therapy: the YELLOW trial (reduction in yellow plaque by aggressive lipid-lowering therapy).
    Kini AS, Baber U, Kovacic JC, et al. · J Am Coll Cardiol · 2013 · Background
    PubMed: PMID 23644090 · NCT04719221 · Acute Coronary Syndrome
  13. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study.
    Giugliano RP, Desai NR, Kohli P, et al. · Lancet · 2013 · Background
    PubMed: PMID 23141813 · NCT01380730 (LAPLACE) · Hypercholesterolemia
  14. Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins.
    Dias CS, Shaywitz AJ, Wasserman SM, et al. · J Am Coll Cardiol · 2013 · Background
    PubMed: PMID 23083772 · NCT01133522 · Hyperlipidemias
  15. Classification of acute pancreatitis--2012: revision of the Atlanta classification and definitions by international consensus.
    Banks PA, Bollen TL, Dervenis C, et al. · Gut · 2013 · Background
    PubMed: PMID 23100216 · NCT07388420

2012 (10 papers)

  1. Dietary cholesterol intake and cancer.
    Hu J, La Vecchia C, de Groh M, et al. · Ann Oncol · 2012 · Trial result
    PubMed: PMID 21543628 · NCT05976893 · Atherosclerosis
  2. In vivo characterization of coronary plaques: novel findings from comparing greyscale and virtual histology intravascular ultrasound and near-infrared spectroscopy.
    Pu J, Mintz GS, Brilakis ES, et al. · Eur Heart J · 2012 · Background
    PubMed: PMID 22019821 · NCT04719221 · Acute Coronary Syndrome
  3. Immediate antioxidant and antiplatelet effect of atorvastatin via inhibition of Nox2.
    Pignatelli P, Carnevale R, Pastori D, et al. · Circulation · 2012 · Background
    PubMed: PMID 22615342 · NCT03331666 · Hypercholesterolemia
  4. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts).
    Perk J, De Backer G, Gohlke H, et al. · Eur Heart J · 2012 · Background
    PubMed: PMID 22555213 · NCT04397653 · Hypercholesterolemia
  5. Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin.
    Owens AP, Passam FH, Antoniak S, et al. · J Clin Invest · 2012 · Background
    PubMed: PMID 22214850 · NCT03331666 · Hypercholesterolemia
  6. The index of microcirculatory resistance predicts myocardial infarction related to percutaneous coronary intervention.
    Ng MK, Yong AS, Ho M, et al. · Circ Cardiovasc Interv · 2012 · Background
    PubMed: PMID 22874078 · NCT04338165 (MICROPROTECT) · Atherosclerosis
  7. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.
    Levine GN, Bates ER, Blankenship JC, et al. · J Am Coll Cardiol · 2012 · Background
    PubMed: PMID 22070834 · NCT04719221 · Acute Coronary Syndrome
  8. Design and rationale of the LAPLACE-TIMI 57 trial: a phase II, double-blind, placebo-controlled study of the efficacy and tolerability of a monoclonal antibody inhibitor of PCSK9 in subjects with hypercholesterolemia on background statin therapy.
    Kohli P, Desai NR, Giugliano RP, et al. · Clin Cardiol · 2012 · Background
    PubMed: PMID 22714699 · NCT01380730 (LAPLACE) · Hypercholesterolemia
  9. Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels.
    Ferri N, Tibolla G, Pirillo A, et al. · Atherosclerosis · 2012 · Background
    PubMed: PMID 22176652 · NCT04338165 (MICROPROTECT) · Atherosclerosis
  10. 2012 American College of Cardiology Foundation/Society for Cardiovascular Angiography and Interventions expert consensus document on cardiac catheterization laboratory standards update: A report of the American College of Cardiology Foundation Task Force on Expert Consensus documents developed in collaboration with the Society of Thoracic Surgeons and Society for Vascular Medicine.
    Bashore TM, Balter S, Barac A, et al. · J Am Coll Cardiol · 2012 · Background
    PubMed: PMID 22575325 · NCT04719221 · Acute Coronary Syndrome

2011 (4 papers)

  1. The efficacy and safety of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors in chronic kidney disease, dialysis, and transplant patients.
    Olyaei A, Greer E, Delos Santos R, et al. · Clin J Am Soc Nephrol · 2011 · Background
    PubMed: PMID 21393488 · NCT04608474 · Hypercholesterolemia
  2. The impact of pravastatin pre-treatment on periprocedural microcirculatory damage in patients undergoing percutaneous coronary intervention.
    Fujii K, Kawasaki D, Oka K, et al. · JACC Cardiovasc Interv · 2011 · Background
    PubMed: PMID 21596324 · NCT04338165 (MICROPROTECT) · Atherosclerosis
  3. In vivo CYP3A activity is significantly lower in cyclosporine-treated as compared with tacrolimus-treated renal allograft recipients.
    de Jonge H, de Loor H, Verbeke K, et al. · Clin Pharmacol Ther · 2011 · Background
    PubMed: PMID 21753749 · NCT04608474 · Hypercholesterolemia
  4. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.
    Baigent C, Landray MJ, Reith C, et al. · Lancet · 2011 · Background
    PubMed: PMID 21663949 · NCT04659525 · Hypercholesterolemia

2010 (4 papers)

  1. Monocytes: protagonists of infarct inflammation and repair after myocardial infarction.
    Nahrendorf M, Pittet MJ, Swirski FK, et al. · Circulation · 2010 · Background
    PubMed: PMID 20530020 · NCT03829046 · Atherosclerosis
  2. Predicting coronary heart disease after kidney transplantation: Patient Outcomes in Renal Transplantation (PORT) Study.
    Israni AK, Snyder JJ, Skeans MA, et al. · Am J Transplant · 2010 · Background
    PubMed: PMID 20415903 · NCT04608474 · Hypercholesterolemia
  3. Genetic variants associated with Lp(a) lipoprotein level and coronary disease.
    Clarke R, Peden JF, Hopewell JC, et al. · N Engl J Med · 2010 · Background
    PubMed: PMID 20032323 · NCT04613167 (GEBI) · Dyslipidemias
  4. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.
    Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, et al. · Lancet · 2010 · Background
    PubMed: PMID 21067804 · NCT04608474 · Hypercholesterolemia

2009 (7 papers)

  1. The early prediction of mortality in acute pancreatitis: a large population-based study.
    Wu BU, Johannes RS, Sun X, et al. · Gut · 2009 · Background
    PubMed: PMID 18519429 · NCT07388420
  2. Genome-wide association study of plasma lipoprotein(a) levels identifies multiple genes on chromosome 6q.
    Ober C, Nord AS, Thompson EE, et al. · J Lipid Res · 2009 · Background
    PubMed: PMID 19124843 · NCT04613167 (GEBI) · Dyslipidemias
  3. Use of cardioprotective medications in kidney transplant recipients.
    Gaston RS, Kasiske BL, Fieberg AM, et al. · Am J Transplant · 2009 · Background
    PubMed: PMID 19519808 · NCT04608474 · Hypercholesterolemia
  4. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.
    Fellström BC, Jardine AG, Schmieder RE, et al. · N Engl J Med · 2009 · Background
    PubMed: PMID 19332456 · NCT04659525 · Hypercholesterolemia
  5. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality.
    Emerging Risk Factors Collaboration, Erqou S, Kaptoge S, et al. · JAMA · 2009 · Background
    PubMed: PMID 19622820 · NCT04613167 (GEBI) · Dyslipidemias
  6. Identifying specific causes of kidney allograft loss.
    El-Zoghby ZM, Stegall MD, Lager DJ, et al. · Am J Transplant · 2009 · Background
    PubMed: PMID 19191769 · NCT04608474 · Hypercholesterolemia
  7. Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy.
    Chasman DI, Shiffman D, Zee RY, et al. · Atherosclerosis · 2009 · Background
    PubMed: PMID 18775538 · NCT04613167 (GEBI) · Dyslipidemias

2007 (2 papers)

  1. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance.
    Neuvonen PJ, Niemi M, Backman JT, et al. · Clin Pharmacol Ther · 2007 · Background
    PubMed: PMID 17178259 · NCT04608474 · Hypercholesterolemia
  2. Role of endothelial shear stress in the natural history of coronary atherosclerosis and vascular remodeling: molecular, cellular, and vascular behavior.
    Chatzizisis YS, Coskun AU, Jonas M, et al. · J Am Coll Cardiol · 2007 · Background
    PubMed: PMID 17599600 · NCT03829046 · Atherosclerosis

2006 (6 papers)

  1. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial.
    Ray KK, Cannon CP, McCabe CH, et al. · J Am Coll Cardiol · 2006 · Trial result
    PubMed: PMID 16226162 · NCT03287609 (EVOPACS) · Acute Coronary Syndrome
  2. Atorvastatin and quinapril inhibit blood coagulation in patients with coronary artery disease following 28 days of therapy.
    Undas A, Brummel-Ziedins KE, Potaczek DP, et al. · J Thromb Haemost · 2006 · Background
    PubMed: PMID 16907931 · NCT03331666 · Hypercholesterolemia
  3. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force.
    McKenney JM, Davidson MH, Jacobson TA, et al. · Am J Cardiol · 2006 · Background
    PubMed: PMID 16581336 · NCT04608474 · Hypercholesterolemia
  4. Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus.
    Lemahieu WP, Hermann M, Asberg A, et al. · Am J Transplant · 2006 · Background
    PubMed: PMID 16095503 · NCT04608474 · Hypercholesterolemia
  5. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study.
    Holdaas H, Fellström B, Cole E, et al. · Am J Transplant · 2006 · Background
    PubMed: PMID 16303007 · NCT04608474 · Hypercholesterolemia
  6. The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis.
    Alsheikh-Ali AA, Ambrose MS, Kuvin JT, et al. · Circulation · 2006 · Background
    PubMed: PMID 15911706 · NCT04608474 · Hypercholesterolemia

2005 (2 papers)

  1. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.
    Wanner C, Krane V, März W, et al. · N Engl J Med · 2005 · Background
    PubMed: PMID 16034009 · NCT04659525 · Hypercholesterolemia
  2. Lipopolysaccharide is transferred from high-density to low-density lipoproteins by lipopolysaccharide-binding protein and phospholipid transfer protein.
    Levels JH, Marquart JA, Abraham PR, et al. · Infect Immun · 2005 · Background
    PubMed: PMID 15784577 · NCT03869073 (PLEASe) · Infections

2004 (3 papers)

  1. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative.
    Kasiske B, Cosio FG, Beto J, et al. · Am J Transplant · 2004 · Background
    PubMed: PMID 15027968 · NCT04608474 · Hypercholesterolemia
  2. Distinct endothelial phenotypes evoked by arterial waveforms derived from atherosclerosis-susceptible and -resistant regions of human vasculature.
    Dai G, Kaazempur-Mofrad MR, Natarajan S, et al. · Proc Natl Acad Sci U S A · 2004 · Background
    PubMed: PMID 15466704 · NCT03829046 · Atherosclerosis
  3. Endothelial function predicts future development of coronary artery disease: a study of women with chest pain and normal coronary angiograms.
    Bugiardini R, Manfrini O, Pizzi C, et al. · Circulation · 2004 · Background
    PubMed: PMID 15136498 · NCT04338165 (MICROPROTECT) · Atherosclerosis

2003 (4 papers)

  1. Statin-associated myopathy.
    Thompson PD, Clarkson P, Karas RH, et al. · JAMA · 2003 · Background
    PubMed: PMID 12672737 · NCT03193047 · Hypercholesterolemia
  2. Time-dependent effect of statins on platelet function in hypercholesterolaemia.
    Puccetti L, Pasqui AL, Pastorelli M, et al. · Eur J Clin Invest · 2003 · Background
    PubMed: PMID 12534449 · NCT03331666 · Hypercholesterolemia
  3. Distribution and kinetics of lipoprotein-bound lipoteichoic acid.
    Levels JH, Abraham PR, van Barreveld EP, et al. · Infect Immun · 2003 · Background
    PubMed: PMID 12761109 · NCT03869073 (PLEASe) · Infections
  4. Novel index for invasively assessing the coronary microcirculation.
    Fearon WF, Balsam LB, Farouque HM, et al. · Circulation · 2003 · Background
    PubMed: PMID 12821539 · NCT04338165 (MICROPROTECT) · Atherosclerosis

2002 (2 papers)

  1. Prognostic value of coronary vascular endothelial dysfunction.
    Halcox JP, Schenke WH, Zalos G, et al. · Circulation · 2002 · Background
    PubMed: PMID 12163423 · NCT04338165 (MICROPROTECT) · Atherosclerosis
  2. Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy.
    Cipollone F, Mezzetti A, Porreca E, et al. · Circulation · 2002 · Background
    PubMed: PMID 12135935 · NCT03331666 · Hypercholesterolemia

2001 (4 papers)

  1. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.
    Schwartz GG, Olsson AG, Ezekowitz MD, et al. · JAMA · 2001 · Trial result
    PubMed: PMID 11277825 · NCT03287609 (EVOPACS) · Acute Coronary Syndrome
  2. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study.
    Sharrett AR, Ballantyne CM, Coady SA, et al. · Circulation · 2001 · Background
    PubMed: PMID 11535564 · NCT03193047 · Hypercholesterolemia
  3. Distribution and kinetics of lipoprotein-bound endotoxin.
    Levels JH, Abraham PR, van den Ende A, et al. · Infect Immun · 2001 · Background
    PubMed: PMID 11292694 · NCT03869073 (PLEASe) · Infections
  4. Upregulation of CD40 and CD40 ligand (CD154) in patients with moderate hypercholesterolemia.
    Garlichs CD, John S, Schmeisser A, et al. · Circulation · 2001 · Background
    PubMed: PMID 11705814 · NCT03331666 · Hypercholesterolemia

2000 (3 papers)

  1. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction.
    Suwaidi JA, Hamasaki S, Higano ST, et al. · Circulation · 2000 · Background
    PubMed: PMID 10704159 · NCT04338165 (MICROPROTECT) · Atherosclerosis
  2. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease.
    Schächinger V, Britten MB, Zeiher AM, et al. · Circulation · 2000 · Background
    PubMed: PMID 10779454 · NCT04338165 (MICROPROTECT) · Atherosclerosis
  3. Monitoring plasma cardiac troponin I for the detection of myocardial injury after percutaneous transluminal coronary angioplasty.
    Ricchiuti V, Shear WS, Henry TD, et al. · Clin Chim Acta · 2000 · Background
    PubMed: PMID 11074073 · NCT04338165 (MICROPROTECT) · Atherosclerosis

1999 (1 paper)

  1. A common variant of the endothelial nitric oxide synthase (Glu298-->Asp) is a major risk factor for coronary artery disease in the UK.
    Hingorani AD, Liang CF, Fatibene J, et al. · Circulation · 1999 · Background
    PubMed: PMID 10510054 · NCT04613167 (GEBI) · Dyslipidemias

1998 (4 papers)

  1. Laminar shear stress: mechanisms by which endothelial cells transduce an atheroprotective force.
    Traub O, Berk BC · Arterioscler Thromb Vasc Biol · 1998 · Background
    PubMed: PMID 9598824 · NCT03829046 · Atherosclerosis
  2. Increased levels of soluble P-selectin in hypercholesterolemic patients.
    Davì G, Romano M, Mezzetti A, et al. · Circulation · 1998 · Background
    PubMed: PMID 9529262 · NCT03331666 · Hypercholesterolemia
  3. Massive thrombosis produced by fatty acid infusion.
    CONNOR WE, HOAK JC, WARNER ED, et al. · J Clin Invest · 1998 · Background
    PubMed: PMID 14022629 · NCT03331666 · Hypercholesterolemia
  4. Endothelium-dependent dilatation is impaired in young healthy subjects with a family history of premature coronary disease.
    Clarkson P, Celermajer DS, Powe AJ, et al. · Circulation · 1998 · Background
    PubMed: PMID 9396430 · NCT04338165 (MICROPROTECT) · Atherosclerosis

1996 (1 paper)

  1. A NEW SERUM TYPE SYSTEM IN MAN--THE LP SYSTEM.
    BERG K · Acta Pathol Microbiol Scand · 1996 · Background
    PubMed: PMID 14064818 · NCT04613167 (GEBI) · Dyslipidemias

1995 (1 paper)

  1. Lung function testing.
    Connolly CK · Respir Med · 1995 · Background
    PubMed: PMID 7846344 · NCT04710368 (YELLOW III) · Coronary Artery Disease

1994 (1 paper)

  1. Elevated plasma levels of vascular endothelial cell markers in patients with hypercholesterolemia.
    Wada H, Mori Y, Kaneko T, et al. · Am J Hematol · 1994 · Background
    PubMed: PMID 8266915 · NCT03331666 · Hypercholesterolemia

1992 (1 paper)

  1. Weight change and serum lipoproteins in recipients of renal allografts.
    Gonyea JE, Anderson CF · Mayo Clin Proc · 1992 · Background
    PubMed: PMID 1434899 · NCT04608474 · Hypercholesterolemia

1986 (1 paper)

  1. Thrombin binding and response in platelets from patients with dyslipoproteinemias: increased stimulus-response coupling in type II hyperlipoproteinemia.
    Harmon JT, Tandon NN, Hoeg JM, et al. · Blood · 1986 · Background
    PubMed: PMID 3524709 · NCT03331666 · Hypercholesterolemia

1979 (1 paper)

  1. Kinetic model for production and metabolism of very low density lipoprotein triglycerides. Evidence for a slow production pathway and results for normolipidemic subjects.
    Zech LA, Grundy SM, Steinberg D, et al. · J Clin Invest · 1979 · Trial result
    PubMed: PMID 221537 · NCT02948777 · Cardiovascular Diseases

1974 (1 paper)

  1. Platelet function in hyperlipoproteinemia.
    Carvalho AC, Colman RW, Lees RS, et al. · N Engl J Med · 1974 · Background
    PubMed: PMID 4359434 · NCT03331666 · Hypercholesterolemia

Sources and methodology

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).